Data / Research funding / Liver Cancer
Liver Cancer: 536 NIH awards ($644M) to 170 organizations
536 NIH awards ($644M) in the NIH spending category Liver Cancer, to 170 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 536 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| University of Arizona Cancer Center - Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $21,155,920 | July 1, 1997 | July 31, 2027 | THEODORESCU, DAN | reporter.nih.gov |
| Center for Pre-Clinical Cancer Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,277,290 | March 1, 2021 | February 28, 2027 | FRANCIS, JOSEPH | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2023 to 2025 | $10,038,112 | September 21, 2021 | August 31, 2027 | HOYO, CATHRINE | reporter.nih.gov |
| Decoding mechanisms underlying metabolic dysregulation in obesity and digestive cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $6,443,697 | September 20, 2022 | August 31, 2027 | TOBIAS, DEIRDRE KAY | reporter.nih.gov |
| Histidine phosphorylation as a new target for cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $5,690,698 | September 18, 2019 | August 31, 2026 | HUNTER, TONY R. | reporter.nih.gov |
| Targeting the MYC Pathway for the Treatment of Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,931,456 | September 8, 2020 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Metabolic Influences on Complex Tumor Neighborhoods | NIH | National Cancer Institute | 2021 to 2025 | $4,722,150 | August 1, 2017 | July 31, 2030 | SIMON, M. CELESTE | reporter.nih.gov |
| Live-cell Activity Architecture in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,655,641 | August 1, 2015 | July 31, 2029 | ZHANG, JIN | reporter.nih.gov |
| Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences | NIH | National Cancer Institute | 2021 to 2025 | $4,251,467 | April 1, 2021 | March 31, 2026 | DISCHER, DENNIS E. | reporter.nih.gov |
| A novel diagnostic Kit for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $3,993,675 | September 1, 2012 | August 31, 2025 | LU, XUANYONG | reporter.nih.gov |
| Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules | NIH | National Cancer Institute | 2023 to 2025 | $3,858,633 | September 19, 2023 | August 31, 2028 | SINGAL, AMIT | reporter.nih.gov |
| The UCLA Center in Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,825,539 | September 17, 2018 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Clinical Validation Center for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,730,583 | August 3, 2022 | July 31, 2027 | SINGAL, AMIT | reporter.nih.gov |
| Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,678,371 | September 7, 2021 | August 31, 2026 | YUAN, JIAN-MIN | reporter.nih.gov |
| Trial of Statins for Chemoprevention in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,646,155 | September 1, 2021 | August 31, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Risk Stratification for and Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,531,567 | September 13, 2018 | August 31, 2028 | KANWAL, FASIHA | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| Abbreviated MRI for HCC screening in cirrhotic patients | NIH | National Cancer Institute | 2021 to 2024 | $3,461,079 | June 19, 2020 | May 31, 2026 | TAOULI, BACHIR | reporter.nih.gov |
| AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS | NIH | National Cancer Institute | 2021 to 2025 | $3,349,717 | July 1, 2021 | June 30, 2027 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Liquid biopsy and radiomics for liver cancer surveillance | NIH | National Cancer Institute | 2023 to 2025 | $3,338,250 | September 19, 2023 | August 31, 2028 | TAOULI, BACHIR | reporter.nih.gov |
| IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,273,154 | August 1, 2022 | July 31, 2027 | KOLTSOVA, EKATERINA | reporter.nih.gov |
| Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,263,901 | September 26, 2022 | June 30, 2027 | LIM, UNHEE | reporter.nih.gov |
| Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,258,965 | September 6, 2021 | July 31, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,197,232 | January 18, 2021 | December 31, 2026 | ZHU, YAZHEN | reporter.nih.gov |
| Simultaneous MRI/US for real-time liver ablation guidance and confirmation | NIH | National Cancer Institute | 2022 to 2025 | $3,174,892 | August 15, 2022 | July 31, 2027 | HOLMES, JAMES H | reporter.nih.gov |
| Drug eluting injectable biomaterials for next generation chemoembolization | NIH | National Cancer Institute | 2021 to 2025 | $3,173,416 | May 1, 2021 | April 30, 2027 | OKLU, RAHMI | reporter.nih.gov |
| Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,010,755 | March 18, 2021 | February 28, 2027 | KANWAL, FASIHA | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,980,235 | April 1, 2021 | March 31, 2027 | KASEB, AHMED | reporter.nih.gov |
| Molecular Magnetic Resonance of Hepatic Fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,974,604 | July 3, 2019 | March 31, 2028 | CARAVAN, PETER D | reporter.nih.gov |
| Consortium on Translational Research in Early Detection of Liver Cancer:Data Management and Coordinating Center (DMCC) | NIH | National Cancer Institute | 2021 to 2025 | $2,944,568 | September 17, 2018 | August 31, 2028 | FENG, ZIDING | reporter.nih.gov |
| Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,920,314 | August 1, 2016 | August 31, 2027 | DUNCAN, JAMES S | reporter.nih.gov |
| Innate Immune Mechanisms Contributing to Cancer Growth in Obesity | NIH | National Cancer Institute | 2021 to 2025 | $2,914,829 | July 1, 2021 | June 30, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Non-invasive etiology-adjusted precision liver cancer risk prediction | NIH | National Cancer Institute | 2025 | $2,876,456 | August 5, 2025 | July 31, 2029 | HOSHIDA, YUJIN | reporter.nih.gov |
| Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,869,940 | September 23, 2021 | July 31, 2027 | BROWN, ROBERT S | reporter.nih.gov |
| A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,862,121 | September 1, 2021 | June 30, 2026 | KURMASHEVA, RAUSHAN | reporter.nih.gov |
| Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,835,203 | May 1, 2022 | April 30, 2027 | YARCHOAN, MARK | reporter.nih.gov |
| Selective mTORC1 inhibition to prevent and treat NAFLD and NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,795,850 | July 15, 2016 | May 31, 2026 | ARANY, ZOLTAN P | reporter.nih.gov |
| Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,782,634 | September 22, 2022 | August 31, 2027 | SANO, MICHAEL BENJAMIN | reporter.nih.gov |
| Multi-cancer early detection using cell-free DNA methylome analysis | NIH | National Cancer Institute | 2023 to 2025 | $2,757,500 | September 19, 2023 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Searching the blood metabolome to identify risk biomarkers for biliary tract cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,714,799 | May 1, 2022 | April 30, 2027 | SHU, XIAO-OU | reporter.nih.gov |
| Covalent Chemistry on Nanosubstrates Enables Molecular Analysis of Purified Extracellular Vesicles in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $2,695,903 | July 7, 2020 | June 30, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Hereditary Genetics of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,655,540 | February 1, 2022 | June 30, 2027 | WANGENSTEEN, KIRK J | reporter.nih.gov |
| Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,637,669 | June 3, 2016 | February 28, 2027 | BERETTA, LAURA | reporter.nih.gov |
| Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net Organizations | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,613,442 | December 22, 2021 | November 30, 2026 | WONG, ROBERT JOHN | reporter.nih.gov |
| Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,603,837 | August 1, 2022 | June 30, 2027 | LI, CHUN | reporter.nih.gov |
| Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,599,664 | September 23, 2021 | August 31, 2025 | HETTS, STEVEN WILLIAM | reporter.nih.gov |
| Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering. | NIH | National Institute on Aging | 2021 to 2025 | $2,597,894 | September 30, 2021 | August 31, 2026 | LOWE, SCOTT W. | reporter.nih.gov |
| Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR) | NIH | National Cancer Institute | 2021 to 2024 | $2,581,284 | September 10, 2020 | August 31, 2025 | JARNAGIN, WILLIAM ROBERT | reporter.nih.gov |
| Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,557,384 | April 12, 2021 | March 31, 2026 | JUON, HEE-SOON | reporter.nih.gov |
| New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,544,474 | September 6, 2022 | June 30, 2027 | WU, HOLDEN H | reporter.nih.gov |
| Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC | NIH | National Cancer Institute | 2021 to 2025 | $2,533,680 | July 20, 2021 | June 30, 2026 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Design and characterization of bacterial population dynamics in solid tumor models | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,515,679 | August 1, 2021 | April 30, 2025 | HASTY, JEFF M | reporter.nih.gov |
| IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,490,304 | January 17, 2022 | October 31, 2025 | HECZEY, ANDRAS A. | reporter.nih.gov |
| Radiation and dendritic cells to hepatomas to improve immunotherapy response | NIH | National Cancer Institute | 2022 to 2025 | $2,485,861 | September 1, 2022 | August 31, 2027 | PARK, SEAN S | reporter.nih.gov |
| The role of AEG-1 in NASH and NASH-HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,484,379 | July 25, 2016 | December 31, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| SPATIALLY MAPPING OF POOLED IN VIVO CRISPR SCREENS IN THE TUMOR MICROENVIRONMENT | NIH | National Cancer Institute | 2022 to 2025 | $2,452,762 | September 26, 2022 | August 31, 2027 | GAUBLOMME, JELLERT | reporter.nih.gov |
| Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,446,660 | December 1, 2019 | November 30, 2024 | NEDROW, JESSIE | reporter.nih.gov |
| Developing Methods for Precise, Safe and Target-location Specific Histotripsy of Liver Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,424,900 | September 23, 2021 | August 31, 2026 | ZIEMLEWICZ, TIMOTHY J | reporter.nih.gov |
| Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC | NIH | National Cancer Institute | 2021 to 2024 | $2,424,874 | August 1, 2020 | April 30, 2026 | MONGA, SATDARSHAN SINGH | reporter.nih.gov |
| A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,413,221 | August 15, 2022 | May 31, 2027 | AVERKIOU, MICHALAKIS | reporter.nih.gov |
| Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | NIH | National Cancer Institute | 2021 to 2024 | $2,400,000 | August 16, 2021 | August 31, 2025 | LAM, SIU KIT | reporter.nih.gov |
| The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,345,542 | August 1, 2022 | November 30, 2025 | KARIN, MICHAEL | reporter.nih.gov |
| The role of IL-17 signaling in alcohol-induced HCC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,322,600 | August 6, 2021 | May 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors | NIH | National Cancer Institute | 2021 to 2022 | $2,286,178 | August 1, 2012 | July 31, 2024 | PENG, YONGREN BENJAMIN | reporter.nih.gov |
| Reverse-engineering precision liver cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $2,262,334 | September 23, 2019 | August 31, 2025 | HOSHIDA, YUJIN | reporter.nih.gov |
| Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,252,988 | February 12, 2021 | January 31, 2026 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| Dynamic Nuclear Polarization MR Spectroscopic Imaging for Diagnosis and Treatment Response Assessment in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,238,522 | January 5, 2022 | December 31, 2026 | GADE, TERENCE P | reporter.nih.gov |
| Southern Liver Health Cohort | NIH | National Cancer Institute | 2021 to 2022 | $2,219,249 | September 21, 2021 | August 31, 2023 | HOYO, CATHRINE | reporter.nih.gov |
| Novel Targeted Combinatorial Therapy for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $2,195,262 | December 1, 2019 | November 30, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| Role of heat shock transcription factor HSF1 in tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,193,704 | July 1, 1996 | January 31, 2027 | MIVECHI, NAHID F | reporter.nih.gov |
| TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction | NIH | National Cancer Institute | 2022 to 2025 | $2,191,917 | April 1, 2022 | March 31, 2027 | PHILIP, MARY | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Integrative Liver Cell Core | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,169,055 | June 15, 2001 | May 31, 2027 | TSUKAMOTO, HIDEKAZU | reporter.nih.gov |
| Regulation of tumor-infiltrating T cells by macrophages | NIH | National Cancer Institute | 2021 to 2025 | $2,167,459 | June 15, 2021 | May 31, 2027 | HUANG, XIAOPEI | reporter.nih.gov |
| Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,167,149 | July 16, 2019 | June 30, 2028 | DAVIDSON, NICHOLAS O. | reporter.nih.gov |
| Exosomal biomarkers for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $2,166,339 | August 8, 2023 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| Unlocking the Chemical Space of Cancer-Associated Perturbations | NIH | National Cancer Institute | 2022 to 2025 | $2,158,944 | September 14, 2022 | August 31, 2027 | BRADY, DONITA C | reporter.nih.gov |
| Integrated analysis of HCC CTCs for Liver Transplant Candidate Selection | NIH | National Cancer Institute | 2021 to 2024 | $2,139,039 | April 1, 2020 | March 31, 2026 | AGOPIAN, VATCHE | reporter.nih.gov |
| Mechanisms of microcystin-induced hepatocellular carcinoma in nonalcoholic steatohepatitis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,132,242 | January 19, 2021 | October 31, 2026 | CLARKE, JOHN DANIEL | reporter.nih.gov |
| A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,131,677 | September 1, 2025 | August 31, 2027 | KOH, MEI YEE | reporter.nih.gov |
| Innovative Genetic Approaches to Enhance Liver Repopulation and Reduce Cancer Risk and Progression | NIH | National Cancer Institute | 2021 to 2024 | $2,128,341 | July 15, 2020 | June 30, 2025 | KAESTNER, KLAUS H | reporter.nih.gov |
| Improving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulations | NIH | National Cancer Institute | 2021 to 2024 | $2,123,250 | June 1, 2020 | May 31, 2025 | ZHU, HAO | reporter.nih.gov |
| A novel cholinergic circuitry in alcoholic liver disease (NIAAA) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,066,485 | March 15, 2021 | January 31, 2027 | WU, JUN | reporter.nih.gov |
| A novel pathway controls liver injury in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,058,572 | June 23, 2022 | March 31, 2027 | ZHAO, PENG | reporter.nih.gov |
| International Consortium for the Genetics of Biliary Tract Cancers Cholangiocarcinoma Genome Wide Association Study | NIH | National Cancer Institute | 2023 to 2025 | $2,005,621 | April 10, 2023 | March 31, 2028 | ROBERTS, LEWIS R | reporter.nih.gov |
| Elucidating dietary fructose and alcohol interactions during liver cancer development | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,001,964 | August 1, 2021 | May 31, 2027 | JANG, CHOLSOON | reporter.nih.gov |
| Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | April 6, 2020 | July 31, 2025 | SHAFIRSTEIN, GAL | reporter.nih.gov |
| Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | September 19, 2023 | August 31, 2025 | SCHACHTSCHNEIDER, KYLE | reporter.nih.gov |
| 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors | NIH | National Cancer Institute | 2023 to 2024 | $1,998,400 | September 19, 2023 | August 31, 2025 | MARATHI, UPENDRA | reporter.nih.gov |
| MethylScan for Early Detection of Liver and Lung Cancer | NIH | National Cancer Institute | 2022 to 2023 | $1,994,570 | June 1, 2020 | March 31, 2025 | NI, XIAOHUI | reporter.nih.gov |
| Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,984,827 | September 14, 2023 | August 31, 2026 | TSENG, HSIAN-RONG | reporter.nih.gov |
| Tumor-promoting liver injuries and mechanisms | NIH | National Cancer Institute | 2021 to 2024 | $1,966,473 | February 20, 2020 | January 31, 2026 | FENG, GEN-SHENG | reporter.nih.gov |
| Click Chemistry-Mediated Surface Protein Assay for Quantifying Subpopulations of Hepatocellular Carcinoma-associated Extracellular Vesicles | NIH | National Cancer Institute | 2023 to 2025 | $1,964,033 | July 1, 2023 | June 30, 2028 | ZHU, YAZHEN | reporter.nih.gov |
| Hepatic stellate cells in NASH fibrosis and HCC | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,960,030 | April 1, 2021 | March 31, 2025 | FRIEDMAN, SCOTT L. | reporter.nih.gov |
| Novel noncanonical actions of CAR in human Liver | NIH | National Cancer Institute | 2021 to 2025 | $1,954,462 | July 6, 2021 | June 30, 2027 | WANG, HONGBING | reporter.nih.gov |
| Interferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,950,900 | December 1, 2021 | November 30, 2026 | MOSCAT, JORGE | reporter.nih.gov |
| San Diego Cirrhosis Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,949,305 | September 9, 2021 | July 31, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Virally-induced tumorigenesis controlled by the microbiota | NIH | National Cancer Institute | 2021 to 2025 | $1,946,266 | July 1, 2019 | February 28, 2030 | GOLOVKINA, TATYANA V | reporter.nih.gov |
| Advanced C-arm imaging platform for histotripsy treatment of liver tumors | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,929,996 | January 1, 2022 | November 30, 2026 | LAESEKE, PAUL F | reporter.nih.gov |
| Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach | NIH | National Cancer Institute | 2021 to 2025 | $1,928,339 | May 1, 2012 | June 30, 2027 | LUBMAN, DAVID M. | reporter.nih.gov |
| Functions of mutant IDH in cholangiocarcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,927,919 | September 20, 2023 | August 31, 2028 | EL-BARDEESY, NABEEL | reporter.nih.gov |
| Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,923,553 | September 1, 2022 | August 31, 2027 | GREEN, CHRISTOPHER D | reporter.nih.gov |
| Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2022 | $1,915,170 | April 3, 2018 | November 30, 2024 | SINGAL, AMIT | reporter.nih.gov |
| Dissecting the NRG4 hormonal checkpoint in metabolic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,912,088 | July 15, 2015 | June 30, 2025 | LIN, JIANDIE D | reporter.nih.gov |
| virtual compound screening using gene expression | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,911,280 | August 1, 2022 | May 31, 2027 | CHEN, BIN | reporter.nih.gov |
| The role of DNAJB1-PKAc-β-catenin axis in fibrolamellar HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,896,102 | April 1, 2023 | March 31, 2028 | TIMCHENKO, NIKOLAI A. | reporter.nih.gov |
| In vivo prime editing for precision cancer mouse models | NIH | National Cancer Institute | 2023 to 2025 | $1,892,549 | August 17, 2023 | July 31, 2028 | XUE, WEN | reporter.nih.gov |
| Role of HCV exosomes in intercellular communication | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,877,240 | April 15, 2020 | February 28, 2026 | HAHN, YOUNG S. | reporter.nih.gov |
| A new mechanism of hepatocyte proliferation under stress | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,872,196 | March 1, 2021 | February 28, 2026 | FENG, GEN-SHENG | reporter.nih.gov |
| Advancing MRI technology for early diagnosis of liver metastases | NIH | National Cancer Institute | 2021 to 2024 | $1,861,579 | December 1, 2019 | November 30, 2025 | ALTBACH, MARIA I. | reporter.nih.gov |
| Molecular mechanisms of focal adhesion kinase in promoting hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,861,075 | July 2, 2015 | December 31, 2026 | QIU, WEI | reporter.nih.gov |
| Ornithine Aminotransferase Inactivation, a New Approach for Treatment of Cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,858,938 | April 15, 2021 | March 31, 2026 | SILVERMAN, RICHARD B | reporter.nih.gov |
| Integrated Informatic and Experimental Evaluations of Cancer Chronotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,815,681 | April 3, 2019 | March 31, 2025 | ANAFI, RON C. | reporter.nih.gov |
| Pathogenic Role of Foxl1+ Hepatic Progenitor Cells in Fibrotic Liver Disease | NIH | National Cancer Institute | 2021 to 2025 | $1,813,542 | December 1, 2023 | November 30, 2026 | SHIN, SOONA | reporter.nih.gov |
| Mechanisms of tumor initiation upon disruption of the Rb/E2f interaction | NIH | National Cancer Institute | 2021 to 2025 | $1,808,391 | April 1, 2021 | June 30, 2027 | VIATOUR, PATRICK | reporter.nih.gov |
| Lipid Metabolism in Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,804,381 | July 15, 2021 | June 30, 2026 | DONG, BINGNING | reporter.nih.gov |
| Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,750 | April 1, 2020 | March 31, 2026 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| Local Tumoral Delivered Immune Checkpoint Blockades Immunotherapy and Radioembolization Combination Therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,763,601 | September 1, 2023 | August 31, 2028 | KIM, DONG-HYUN | reporter.nih.gov |
| Investigating multifactorial beta-catenin activation in hepatocellular cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,760,894 | March 1, 2022 | July 9, 2026 | CHEN, XIN | reporter.nih.gov |
| Yittrium-90 radiation lobectomy: Dose optimization and prediction of FLR hypertrophy to enable resection of HCC | NIH | National Cancer Institute | 2022 to 2025 | $1,755,197 | August 1, 2019 | July 31, 2026 | LEWANDOWSKI, ROBERT J | reporter.nih.gov |
| Development of an INSPIRE System for the Treatment of Inoperable Liver Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,733,529 | April 14, 2023 | March 31, 2028 | SANO, MICHAEL BENJAMIN | reporter.nih.gov |
| Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5A | NIH | National Cancer Institute | 2021 to 2023 | $1,722,094 | July 1, 2020 | June 30, 2024 | FUJIMORI, DANICA GALONIC | reporter.nih.gov |
| Role of STEAP2 protein in hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,714,309 | July 1, 2020 | June 30, 2026 | SUN, LUZHE | reporter.nih.gov |
| Quantitative PET Imaging of Hepatocellular Carcinoma (HCC) | NIH | National Cancer Institute | 2021 to 2024 | $1,706,571 | September 22, 2020 | August 31, 2025 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Cell targeting with synthetic sense-and-respond protease circuits | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,691,400 | September 1, 2020 | May 31, 2025 | ELOWITZ, MICHAEL B | reporter.nih.gov |
| Matrix in pre-cirrhotic HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,687,806 | March 15, 2023 | February 29, 2028 | TOROK, NATALIE J. | reporter.nih.gov |
| Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,686,928 | August 15, 2020 | April 30, 2024 | DAHL, JEREMY | reporter.nih.gov |
| Intra- and inter-cellular signals that drive hepato-oncogenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,670,574 | February 10, 2020 | January 31, 2026 | FENG, GEN-SHENG | reporter.nih.gov |
| ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $1,659,105 | June 1, 2020 | May 31, 2025 | SIMON, SANFORD M | reporter.nih.gov |
| Role of SAMe in the Progression of Nonalcoholic Fatty Liver Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,656,555 | September 20, 2002 | June 30, 2026 | LU, SHELLY CHI-LOO | reporter.nih.gov |
| Role of Base Excision Repair in Limiting Hepatocellular Carcinomas | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,650,684 | January 1, 2020 | October 31, 2024 | LLOYD, R. STEPHEN | reporter.nih.gov |
| Understanding mechanisms of liver carcinogenesis following developmental BPA exposure | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,644,363 | December 20, 2022 | October 31, 2027 | WEINHOUSE, CAREN | reporter.nih.gov |
| Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors | NIH | National Cancer Institute | 2021 to 2023 | $1,637,378 | December 1, 2018 | November 30, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Glycopathology of HCC: identification of the source cells of serum fucosylation | NIH | National Cancer Institute | 2021 to 2023 | $1,620,312 | March 14, 2019 | February 28, 2025 | MEHTA, ANAND S. | reporter.nih.gov |
| Novel coagulation-dependent mechanisms of liver regeneration to detect and prevent liver dysfunction after partial hepatectomy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,615,336 | July 1, 2020 | June 30, 2026 | LUYENDYK, JAMES P | reporter.nih.gov |
| Identifying therapeutic options for intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,588,482 | April 15, 2021 | March 31, 2027 | KO, SUNGJIN | reporter.nih.gov |
| Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,574,167 | April 1, 2021 | March 31, 2027 | KUGEL, SITA | reporter.nih.gov |
| Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,539,465 | March 1, 2022 | February 28, 2027 | SIEGWART, DANIEL JOHN | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,531,257 | August 15, 2020 | June 30, 2023 | WEISS, STANLEY H | reporter.nih.gov |
| O-glycoproteins in the progression of liver disease | NIH | National Cancer Institute | 2021 to 2023 | $1,525,161 | July 1, 2019 | June 30, 2024 | GOLDMAN, RADOSLAV | reporter.nih.gov |
| Mechanistic studies of transcription initiation and elongation functions of an RNA polymerase II variant, Pol II(G), that is implicated in development and cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,523,785 | July 25, 2022 | June 30, 2027 | ROEDER, ROBERT G | reporter.nih.gov |
| Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $1,521,577 | July 1, 2018 | June 30, 2025 | LUJAMBIO, AMAIA | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2022 to 2023 | $1,519,485 | July 1, 2022 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,518,039 | July 18, 2018 | March 31, 2029 | MISHRA, LOPA | reporter.nih.gov |
| Oncometabolites, DNA Repair, and Cancer | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,507,500 | September 30, 1992 | December 31, 2026 | GLAZER, PETER M | reporter.nih.gov |
| Therapeutic targeting of FGF19-driven cancers with FGF21 variants | NIH | National Cancer Institute | 2022 to 2025 | $1,505,804 | July 15, 2022 | June 30, 2027 | LEE, SANGWON | reporter.nih.gov |
| Using ethics, epidemiology and high-quality data to optimize the allocation of livers for transplantation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,498,133 | April 1, 2019 | March 31, 2025 | GOLDBERG, DAVID SETH | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,471,222 | August 15, 2020 | June 30, 2027 | WEISS, STANLEY H | reporter.nih.gov |
| MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,463,868 | August 22, 2022 | July 31, 2027 | SONG, GUISHENG | reporter.nih.gov |
| Translation of a biomarker panel for the early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,458,768 | September 18, 2019 | August 31, 2024 | MEHTA, ANAND S. | reporter.nih.gov |
| Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,450,638 | September 25, 2018 | August 31, 2024 | KARIN, MICHAEL | reporter.nih.gov |
| Image-guided Interventional Combination Liver Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $1,441,665 | March 1, 2021 | February 28, 2026 | ZHANG, ZHUOLI | reporter.nih.gov |
| A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,439,465 | June 1, 2019 | May 31, 2024 | SARKAR, DEVANAND | reporter.nih.gov |
| Adhesive regulation during cell migration | NIH | National Cancer Institute | 2022 to 2025 | $1,432,752 | June 10, 2000 | November 30, 2026 | HUTTENLOCHER, ANNA | reporter.nih.gov |
| Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis | NIH | National Cancer Institute | 2021 to 2024 | $1,430,166 | December 1, 2019 | November 30, 2025 | MCLACHLAN, ALAN | reporter.nih.gov |
| Nanoparticle CT Contrast Agent for New Capabilities in Tumor Detection, Staging, and Therapy Planning and Response | NIH | National Cancer Institute | 2021 to 2022 | $1,429,565 | May 1, 2019 | April 30, 2024 | YEH, BENJAMIN M | reporter.nih.gov |
| Glutamine synthetase in beta-catenin driven hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $1,426,897 | September 1, 2018 | May 31, 2029 | ZONG, WEI-XING | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2024 to 2025 | $1,426,107 | July 1, 2022 | June 30, 2027 | ZHANG, XUEHONG | reporter.nih.gov |
| Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States | NIH | National Cancer Institute | 2021 to 2022 | $1,420,632 | September 14, 2018 | July 31, 2025 | SINGAL, AMIT | reporter.nih.gov |
| Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,416,386 | January 1, 2023 | December 31, 2027 | MA, LI | reporter.nih.gov |
| Telomere dysfunction and telomerase reactivation in the etiology and progression of liver cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,415,906 | December 13, 2021 | November 30, 2026 | BATISTA, LUIS FRANCISCO ZIRNBERGER | reporter.nih.gov |
| Targeting PLK1 signaling for the treatment of fibrolamellar carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,415,175 | August 1, 2023 | July 31, 2028 | GUJRAL, TARAN SINGH | reporter.nih.gov |
| Determinants of immunotherapy response in NASH-Hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,408,891 | August 4, 2023 | July 31, 2028 | LLOVET, JOSEP M | reporter.nih.gov |
| PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATION | NIH | National Cancer Institute | 2021 to 2024 | $1,405,770 | February 6, 2020 | January 31, 2026 | LEE, JU-SEOG | reporter.nih.gov |
| Multispectral imaging of bile duct epithelial morphology for early detection of malignancy | NIH | National Cancer Institute | 2024 to 2025 | $1,398,638 | July 1, 2024 | June 30, 2029 | PERELMAN, LEV T | reporter.nih.gov |
| Anti-cancer vaccine targeting the host-parasite interface during fluke infection | NIH | National Cancer Institute | 2021 to 2025 | $1,391,200 | September 21, 2012 | August 31, 2029 | BRINDLEY, PAUL J | reporter.nih.gov |
| A proteomics atlas of HIV/HBV infections for curing HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,381,244 | August 1, 2024 | June 30, 2029 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,381,209 | September 23, 2021 | April 18, 2024 | STAVELEY-O'CARROLL, KEVIN FINNBAR | reporter.nih.gov |
| Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,379,767 | May 1, 2023 | April 30, 2028 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Elimination Racial Disparities in Hepatocellular Carcinoma | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,378,034 | March 26, 2024 | April 30, 2027 | SRIVASTAVA, RAKESH K. | reporter.nih.gov |
| An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,371,191 | March 1, 2023 | February 29, 2028 | SHETH, RAHUL ANIL | reporter.nih.gov |
| Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture | NIH | National Cancer Institute | 2023 to 2025 | $1,369,185 | September 21, 2023 | August 31, 2027 | BRANCH, ANDREA D. | reporter.nih.gov |
| Defining the role of CNPY2 in promoting tumor progression through mediation of macrophage. | NIH | National Cancer Institute | 2023 to 2025 | $1,367,928 | February 13, 2023 | January 31, 2028 | HONG, FENG | reporter.nih.gov |
| Development and application of non-thermal high frequency IRE to treat hepatic tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,358,929 | April 1, 2020 | August 9, 2023 | DAVALOS, RAFAEL VIDAL | reporter.nih.gov |
| Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,357,029 | August 1, 2024 | July 31, 2029 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,345,287 | July 1, 2021 | June 30, 2028 | KWEE, SANDI ALEXANDER | reporter.nih.gov |
| Docosahexaenoic Acid Loaded Low-density Lipoproteins: A Novel Biologic Intervention for Hepatocellular Carcinoma. | NIH | National Cancer Institute | 2023 to 2025 | $1,343,213 | December 1, 2022 | November 30, 2027 | CORBIN, IAN RONALD | reporter.nih.gov |
| Tumor Detection and Classification using QUS Technology's Structure Function | NIH | National Cancer Institute | 2021 to 2024 | $1,338,343 | April 10, 2019 | March 31, 2026 | O'BRIEN, WILLIAM D. | reporter.nih.gov |
| Integrating bioinformatics into multiscale models for hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2022 | $1,336,665 | April 17, 2018 | March 31, 2024 | FERTIG, ELANA | reporter.nih.gov |
| Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC) | NIH | National Cancer Institute | 2024 to 2025 | $1,335,826 | June 1, 2024 | May 31, 2029 | YARCHOAN, MARK | reporter.nih.gov |
| Microbubble Cavitation for Improving Hepatocellular Carcinoma Radioembolization | NIH | National Cancer Institute | 2021 to 2024 | $1,332,481 | December 11, 2019 | November 30, 2025 | EISENBREY, JOHN | reporter.nih.gov |
| Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,326,264 | August 15, 2023 | June 30, 2027 | DHAR, DEBANJAN | reporter.nih.gov |
| Deformation Corrected Image Guided Laparoscopic Liver Surgery | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,320,001 | September 16, 2019 | June 30, 2024 | MIGA, MICHAEL IAN | reporter.nih.gov |
| Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis | NIH | National Cancer Institute | 2023 to 2025 | $1,318,215 | September 25, 2023 | August 31, 2027 | HOSHIDA, YUJIN | reporter.nih.gov |
| Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,310,295 | September 19, 2023 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Sympathetic circadian dysfunction in obesity-related hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,308,596 | September 1, 2019 | August 31, 2025 | FU, LONING NONE | reporter.nih.gov |
| Noninvasive High-Resolution Mapping of HCC Tumor Biology Predictive of Malignancy | NIH | National Cancer Institute | 2024 to 2025 | $1,300,171 | March 11, 2024 | February 28, 2029 | CAI, KEJIA | reporter.nih.gov |
| Hepatitis B virus integrations in KMT2B drive hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,297,237 | July 15, 2022 | June 30, 2027 | CAO, JIAN | reporter.nih.gov |
| Targeting Oncogenic PKA signaling mechanisms | NIH | National Cancer Institute | 2024 to 2025 | $1,294,238 | December 15, 2023 | November 30, 2028 | GORDAN, JOHN D | reporter.nih.gov |
| Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC) | NIH | National Cancer Institute | 2024 to 2025 | $1,293,190 | March 1, 2024 | February 28, 2029 | YARCHOAN, MARK | reporter.nih.gov |
| Targeting Ischemia-Induced Dependencies on the Metabolic Stress Response in Hepatocellular Carcinoma Through Image-Guided, Locoregional Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,272,726 | June 1, 2019 | May 31, 2024 | GADE, TERENCE P | reporter.nih.gov |
| 2D and 3D Contrast-enhanced Ultrasound Evaluation of Chemoembolization. | NIH | National Cancer Institute | 2024 to 2025 | $1,270,432 | March 23, 2016 | July 31, 2029 | EISENBREY, JOHN | reporter.nih.gov |
| Epigallocatechin gallate for prevention of lethal cirrhosis complications | NIH | National Cancer Institute | 2023 to 2024 | $1,270,168 | September 6, 2023 | August 31, 2028 | HOSHIDA, YUJIN | reporter.nih.gov |
| Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States | NIH | National Cancer Institute | 2021 to 2023 | $1,249,102 | July 16, 2021 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study | NIH | National Cancer Institute | 2024 to 2025 | $1,232,605 | September 3, 2024 | August 31, 2029 | KIRK, GREGORY D | reporter.nih.gov |
| Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2022 | $1,230,719 | June 19, 2018 | May 31, 2024 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Cyanobacteria, cyanotoxins, and liver cancer development | NIH | National Cancer Institute | 2024 to 2025 | $1,227,270 | May 1, 2024 | April 30, 2029 | HERNANDEZ, BRENDA YUKARI | reporter.nih.gov |
| Dissecting a novel tumor-promoting axis in cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,224,644 | August 13, 2024 | July 31, 2029 | SIA, DANIELA | reporter.nih.gov |
| Targeting an unrecognized checkpoint on T cell function in tumors | NIH | National Cancer Institute | 2021 to 2025 | $1,224,020 | July 1, 2021 | June 30, 2026 | EIL, ROBERT LANGLAND | reporter.nih.gov |
| High-Precision Proton Therapy for Liver Cancer: Developing an End-to-end Strategy with Real-time Liver Tumor Localization and On-the-fly Plan Delivery Adaptation | NIH | National Cancer Institute | 2024 to 2025 | $1,221,878 | March 1, 2024 | February 28, 2029 | ZHANG, YOU | reporter.nih.gov |
| Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,221,780 | September 1, 2024 | August 31, 2029 | PARK, SEAN S | reporter.nih.gov |
| Development of a 3D multi-modal perfusion-thermal electrode system | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,216,145 | April 1, 2019 | December 31, 2024 | YANG, XIAOMING | reporter.nih.gov |
| Active HCV diagnosis to support prevention of HCC in LMICs | NIH | National Cancer Institute | 2024 to 2025 | $1,208,204 | August 9, 2024 | July 31, 2029 | MCFALL, SALLY MAUREEN | reporter.nih.gov |
| Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation | NIH | National Cancer Institute | 2024 to 2025 | $1,208,126 | April 1, 2024 | March 31, 2029 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| Computer Guided Microwave Liver Ablation | NIH | National Cancer Institute | 2024 to 2025 | $1,206,412 | May 1, 2024 | April 30, 2027 | BORSIC, ANDREA | reporter.nih.gov |
| NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION | NIH | National Cancer Institute | 2021 to 2022 | $1,195,410 | September 13, 2018 | August 31, 2024 | LOK, ANNA S.F. | reporter.nih.gov |
| The role of hexokinase 2 in liver fibrosis and NASH-induced HCC | NIH | National Cancer Institute | 2024 to 2025 | $1,194,448 | September 1, 2024 | August 31, 2029 | HAY, NISSIM | reporter.nih.gov |
| A 3D DCE-US Interconnected Voxel Analysis Framework for Bedside Characterization of Tumor Vascular Properties in Liver Malignancies. | NIH | National Cancer Institute | 2024 to 2025 | $1,191,058 | September 16, 2024 | August 31, 2029 | EL KAFFAS, AHMED | reporter.nih.gov |
| Diverging roles of EGFR and MET in acetaminophen-induced acute liver injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,187,643 | April 1, 2023 | December 31, 2027 | BHUSHAN, BHARAT | reporter.nih.gov |
| BNIP3 and BNIP3L (NIX) in lipid homeostasis and growth control in the liver | NIH | National Cancer Institute | 2023 to 2025 | $1,187,134 | March 1, 2016 | May 31, 2028 | MACLEOD, KAY F | reporter.nih.gov |
| Targeting oncogenes for hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,171,644 | April 1, 2019 | March 31, 2025 | SARKAR, DEVANAND | reporter.nih.gov |
| A Novel Druggable Epigenetic Vulnerability Pathway in HCC | NIH | National Cancer Institute | 2021 to 2022 | $1,154,338 | April 1, 2018 | March 31, 2024 | KELLIHER, MICHELLE ALICE | reporter.nih.gov |
| Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors | NIH | National Cancer Institute | 2025 | $1,150,000 | September 16, 2022 | August 31, 2027 | FONG, JORDAN | reporter.nih.gov |
| Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cells | NIH | National Cancer Institute | 2021 to 2023 | $1,140,447 | August 19, 2019 | July 31, 2025 | SCHWARTZ, ROBERT E | reporter.nih.gov |
| Role of CMA failure in NASH progression to Hepatocellular Carcinoma | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,134,000 | May 1, 2020 | April 30, 2025 | ARIAS-PEREZ, ESPERANZA | reporter.nih.gov |
| Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis | NIH | National Cancer Institute | 2024 to 2025 | $1,133,540 | March 1, 2024 | March 2, 2028 | FONT-BURGADA, JOAN | reporter.nih.gov |
| Novel, Noninvasive, Rapid Tumor Ablation Technology using Histotripsy | NIH | National Cancer Institute | 2021 to 2022 | $1,131,313 | January 9, 2018 | December 31, 2023 | XU, ZHEN | reporter.nih.gov |
| Aberration Correction for Histotripsy Ablation of Liver | NIH | National Cancer Institute | 2024 to 2025 | $1,116,460 | May 1, 2024 | April 30, 2029 | HALL, TIMOTHY L | reporter.nih.gov |
| How does a metallofactor in Hepatitis B viral protein X orchestrate pathogenesis and liver cancer | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,115,277 | July 5, 2019 | June 30, 2024 | PANDELIA, MARIA-EIRINI | reporter.nih.gov |
| Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | NIH | National Cancer Institute | 2023 to 2025 | $1,112,955 | February 1, 2023 | January 31, 2028 | SU, YING-HSIU | reporter.nih.gov |
| Accurate 4D Liver Tumor Localization for Radiotherapy using Contrast-Agent-Free X-ray Imaging and Liver Biomechanical Modeling | NIH | National Cancer Institute | 2021 to 2024 | $1,108,895 | June 1, 2020 | May 31, 2026 | ZHANG, YOU | reporter.nih.gov |
| Scanner Agnostic Image-Guided Biopsy Platform Employing Advanced Computer Vision and Computer Graphics to Enable Non-Invasive Registration and Dynamic Projection Mapping | NIH | National Cancer Institute | 2025 | $1,107,943 | September 12, 2025 | August 31, 2027 | HU, JAMES | reporter.nih.gov |
| Development of a novel MYC inhibitor for cancer therapy | NIH | National Cancer Institute | 2025 | $1,102,729 | September 12, 2025 | August 31, 2027 | VOLLRATH, BEN | reporter.nih.gov |
| A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $1,099,610 | September 19, 2023 | August 31, 2028 | KARIN, MICHAEL | reporter.nih.gov |
| DNA-PKcs and PIDD interaction in DNA damage response | NIH | National Cancer Institute | 2021 to 2023 | $1,096,903 | September 1, 2019 | August 31, 2025 | DAVIS, ANTHONY J | reporter.nih.gov |
| TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $1,086,442 | December 7, 2018 | November 30, 2025 | HE, YUKAI | reporter.nih.gov |
| RNA-binding protein HuR in liver pathophysiology and carcinogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,081,164 | July 3, 2019 | April 30, 2025 | ZHANG, YUXIA | reporter.nih.gov |
| Genetic Epidemiology of Hepatocellular Carcinoma in African Americans | NIH | National Cancer Institute | 2023 to 2025 | $1,079,701 | July 26, 2023 | June 30, 2028 | THRIFT, AARON PETER | reporter.nih.gov |
| Hybrid virtual-MRI/CBCT: A new paradigm for image guidance in liver SBRT | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,077,279 | September 30, 2019 | June 30, 2025 | REN, LEI | reporter.nih.gov |
| A liver digital twin for personalized cancer therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,074,605 | September 17, 2024 | August 31, 2027 | RONCALI, EMILIE | reporter.nih.gov |
| The Role of p53-R249S’s GOF in HCC development | NIH | National Cancer Institute | 2021 to 2023 | $1,072,557 | January 1, 2019 | December 31, 2024 | LU, HUA | reporter.nih.gov |
| Immunologic Biomarkers of Rejection in Clinical Liver Transplantation | NIH | National Cancer Institute | 2021 to 2024 | $1,067,480 | June 1, 2020 | May 31, 2026 | EMAMAULLEE, JULIET | reporter.nih.gov |
| Deciphering the role of NELFE in modulating MYC signaling in HCC | NIH | National Cancer Institute | 2023 to 2025 | $1,061,371 | July 10, 2023 | June 30, 2028 | DANG, HIEN T. | reporter.nih.gov |
| Randomized phase II study of TheraBionic in advanced hepatocellular carcinoma | NIH | National Cancer Institute | 2021 | $1,059,091 | September 22, 2021 | August 31, 2023 | PASCHE, VALERIE | reporter.nih.gov |
| Determining biological and behavioral determinants of hepatocellular carcinoma incidence and outcomes | NIH | National Cancer Institute | 2022 to 2025 | $1,054,861 | July 1, 2022 | June 30, 2027 | RICH, NICOLE ELIZABETH | reporter.nih.gov |
| Nuclear envelope and predisposition to hepatic neoplasia | NIH | National Cancer Institute | 2023 to 2025 | $1,049,504 | August 1, 2023 | July 31, 2028 | SHIN, JI-YEON | reporter.nih.gov |
| DNA Adduct-Induced Mutagenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $1,049,108 | February 15, 1992 | June 11, 2024 | STONE, MICHAEL P | reporter.nih.gov |
| Improved early prognostic algorithm for hepatocellulcar carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $1,047,183 | April 1, 2020 | June 30, 2025 | KIM, AMY K | reporter.nih.gov |
| Signaling pathways during hepatocarcinogenesis | NIH | National Cancer Institute | 2022 to 2024 | $1,041,389 | March 1, 2022 | February 28, 2026 | CHEN, XIN | reporter.nih.gov |
| The mitochondrial aspects of health disparity of hepatocellular carcinoma in Hispanic population | NIH | National Cancer Institute | 2023 to 2025 | $1,040,371 | July 1, 2023 | June 30, 2026 | BAI, YIDONG | reporter.nih.gov |
| The Long Noncoding RNA MALAT1 in Liver Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,029,192 | December 6, 2018 | November 30, 2024 | WU, TONG | reporter.nih.gov |
| Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,012,300 | August 15, 2018 | May 31, 2024 | ROBERTSON, KEITH D | reporter.nih.gov |
| Role of protein mediate fatty acid uptake in liver cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,004,324 | August 17, 2018 | July 31, 2024 | STAHL, ANDREAS | reporter.nih.gov |
| Genetic and Environmental risk of NAFLD-related HCC In All Latinos: the GENIAL Study | NIH | National Cancer Institute | 2023 to 2025 | $1,000,316 | September 21, 2023 | August 31, 2027 | JONES, PATRICIA DENISE | reporter.nih.gov |
| Anatomical Modeling to Improve the Precision of Image Guided Liver Ablation | NIH | National Cancer Institute | 2021 to 2023 | $999,364 | September 1, 2019 | August 31, 2025 | BROCK, KRISTY | reporter.nih.gov |
| Liver Specific Manganese Based MRI Contrast Agent | NIH | National Cancer Institute | 2021 | $999,330 | August 8, 2019 | September 30, 2022 | HOFFMAN, VERA | reporter.nih.gov |
| Validation of Clinical Assays for Risk Stratification of Children With Pediatric Liver Neoplasms | NIH | National Cancer Institute | 2023 to 2025 | $982,354 | July 1, 2023 | June 30, 2026 | LOPEZ-TERRADA, DOLORES | reporter.nih.gov |
| Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $980,000 | August 1, 2023 | May 31, 2028 | DHAR, DEBANJAN | reporter.nih.gov |
| Epigenetic Mechanisms of Biliary Epithelial Neoplasia | NIH | National Cancer Institute | 2021 to 2025 | $979,804 | July 1, 2018 | December 31, 2029 | WU, TONG | reporter.nih.gov |
| Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis | NIH | National Cancer Institute | 2021 to 2022 | $976,175 | August 1, 2017 | July 31, 2025 | SINGAL, AMIT | reporter.nih.gov |
| (PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis | NIH | National Cancer Institute | 2021 to 2022 | $967,903 | September 18, 2018 | August 31, 2024 | FU, LONING NONE | reporter.nih.gov |
| Novel biologic RNA molecules to modulate HCC metabolism | NIH | National Cancer Institute | 2024 to 2025 | $967,182 | August 1, 2024 | July 31, 2029 | YU, AIMING | reporter.nih.gov |
| qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents | NIH | National Cancer Institute | 2021 to 2022 | $964,654 | March 1, 2019 | August 31, 2023 | JOHNSTON, PAUL A. | reporter.nih.gov |
| Early detection of HCC using noninvasive activity-based nanosensors | NIH | National Cancer Institute | 2021 | $964,382 | June 1, 2019 | July 31, 2023 | WINCKLER, WENDY | reporter.nih.gov |
| Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer | NIH | National Cancer Institute | 2024 to 2025 | $963,113 | September 23, 2021 | August 31, 2026 | STAVELEY-O'CARROLL, KEVIN FINNBAR | reporter.nih.gov |
| Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer | NIH | National Cancer Institute | 2023 to 2025 | $957,754 | May 1, 2023 | February 28, 2029 | LI, GUANGFU | reporter.nih.gov |
| The Impact of Genetic Ancestry on Racial Disparities in Hepatocellular Carcinoma Risk and Mortality | NIH | National Cancer Institute | 2022 to 2025 | $948,260 | September 15, 2022 | August 31, 2027 | JONES, PATRICIA DENISE | reporter.nih.gov |
| High-risk hepatoblastoma dissemination control by oncogenic NRF2 | NIH | National Cancer Institute | 2024 to 2025 | $925,474 | July 17, 2024 | June 30, 2026 | WOODFIELD, SARAH ELIZABETH | reporter.nih.gov |
| Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $921,328 | April 1, 2019 | March 31, 2027 | TAYOB, NABIHAH | reporter.nih.gov |
| Rapid Motion-Robust and Easy-to-Use Dynamic Contrast-Enhanced MRI for Liver Perfusion Quantification | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $917,160 | July 1, 2021 | March 31, 2023 | FENG, LI | reporter.nih.gov |
| Defective urea cycle promotes oncogenesis of hepatocellular carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $901,994 | July 1, 2024 | June 30, 2029 | ZONG, WEI-XING | reporter.nih.gov |
| Impact of multidisciplinary evaluation of treatment and outcome for hepatocellular carcinoma in Tanzania | NIH | Fogarty International Center | 2025 | $899,426 | September 22, 2025 | August 31, 2030 | GASKILL, CAMERON E | reporter.nih.gov |
| Liver Cancer Therapy by MiR-22 and Its Inducers | NIH | National Cancer Institute | 2021 to 2023 | $876,644 | February 1, 2018 | January 31, 2025 | WAN, YU-JUI YVONNE | reporter.nih.gov |
| Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells | NIH | National Center for Advancing Translational Sciences | 2025 | $865,162 | August 1, 2025 | July 31, 2027 | HAWLEY, BENJAMIN RICHARD | reporter.nih.gov |
| Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis | NIH | National Cancer Institute | 2021 to 2023 | $863,226 | January 1, 2018 | December 31, 2025 | SINGAL, AMIT | reporter.nih.gov |
| Peptide multimer for early detection of hepatocellular carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $843,488 | July 3, 2024 | June 30, 2026 | WANG, THOMAS D | reporter.nih.gov |
| Interplay of bile acid and estrogen signaling | NIH | National Cancer Institute | 2021 to 2022 | $837,820 | January 1, 2018 | December 31, 2023 | DENG, RUITANG | reporter.nih.gov |
| Mutant p53 gain-of-function as an actionable target in cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $828,596 | September 11, 2020 | August 31, 2025 | NEMAJEROVA, ALICE | reporter.nih.gov |
| Role of cholecystokinin receptor in hepatocellular cancer | NIH | National Cancer Institute | 2021 to 2025 | $814,845 | September 1, 2021 | August 31, 2026 | GAY, MARTHA | reporter.nih.gov |
| Novel circulating biomarker digital scores for assessing treatment response in liver cancer | NIH | National Cancer Institute | 2022 to 2024 | $806,601 | September 1, 2022 | August 31, 2025 | YANG, JU DONG | reporter.nih.gov |
| Rapid Motion-Robust and Easy-to-Use Dynamic Contrast-Enhanced MRI for Liver Perfusion Quantification | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $800,366 | May 1, 2023 | March 31, 2026 | FENG, LI | reporter.nih.gov |
| Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $797,641 | April 1, 2020 | March 31, 2026 | ZHANG, BING | reporter.nih.gov |
| Defining pro-metastatic and endothelial-regulatory roles for LIN28B in hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $795,945 | August 1, 2023 | July 31, 2027 | FRANSES, JOSEPH WANG | reporter.nih.gov |
| Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States | NIH | National Cancer Institute | 2024 to 2025 | $793,720 | July 16, 2021 | August 31, 2026 | ZHANG, XUEHONG | reporter.nih.gov |
| Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC) | NIH | National Cancer Institute | 2025 | $793,324 | April 15, 2025 | March 31, 2028 | HUANG, WENDONG | reporter.nih.gov |
| MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors. | NIH | National Cancer Institute | 2024 to 2025 | $789,531 | September 19, 2024 | August 31, 2029 | YEUNG, RAYMOND | reporter.nih.gov |
| (PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting | NIH | National Cancer Institute | 2021 to 2022 | $778,766 | May 22, 2018 | July 31, 2024 | HAJNOCZKY, GYORGY | reporter.nih.gov |
| Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation | NIH | National Cancer Institute | 2025 | $775,669 | July 1, 2023 | August 31, 2028 | ARNOLD, KATELYN | reporter.nih.gov |
| Mechanisms of mitochondrial dynamics, quality control and mtDNA-mediated inflammation in alcohol-associated liver disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $772,738 | August 20, 2024 | May 31, 2029 | DING, WEN-XING | reporter.nih.gov |
| gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention | NIH | National Cancer Institute | 2021 to 2022 | $768,980 | September 10, 2018 | August 31, 2024 | CHUNG, FUNG-LUNG | reporter.nih.gov |
| Cellular and molecular mechanism of Hippo signaling in suppressing liver tumor formation | NIH | National Cancer Institute | 2021 to 2022 | $767,708 | August 30, 2018 | July 31, 2024 | YANG, YINGZI | reporter.nih.gov |
| Role of pseudouridines in pre-mRNA processing | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $746,998 | August 1, 2020 | January 31, 2025 | MARTINEZ, NICOLE | reporter.nih.gov |
| Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers | NIH | National Cancer Institute | 2021 to 2023 | $746,439 | August 12, 2021 | January 31, 2025 | BROHL, ANDREW SCOTT | reporter.nih.gov |
| The Pro-Tumor Immunologic Niche of the Liver | NIH | National Cancer Institute | 2021 to 2023 | $728,694 | September 1, 2019 | August 31, 2024 | ILYAS, SUMERA I. | reporter.nih.gov |
| Role of p62/SQSTM1 in obesity-induced liver cancer | NIH | National Cancer Institute | 2021 | $726,246 | February 15, 2017 | January 31, 2023 | KARIN, MICHAEL | reporter.nih.gov |
| Monitoring and control of human liver cancer ablation using real-time, 3D echo decorrelation imaging | NIH | National Cancer Institute | 2021 to 2022 | $721,239 | August 10, 2012 | May 31, 2025 | MAST, T DOUGLAS | reporter.nih.gov |
| Optimization and Evaluation of Anatomical Models of Liver Radiation Response | NIH | National Cancer Institute | 2021 to 2022 | $717,615 | July 3, 2018 | June 30, 2025 | BROCK, KRISTY | reporter.nih.gov |
| Genomics of HCC in the Hispanic population of Texas | NIH | National Cancer Institute | 2021 to 2022 | $714,156 | April 1, 2018 | March 31, 2024 | BERETTA, LAURA | reporter.nih.gov |
| Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $713,985 | April 1, 2024 | March 31, 2029 | KIM, DONG-HYUN | reporter.nih.gov |
| Extracellular vesicle RNA signaling in liver tumor microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $708,828 | February 8, 2018 | January 31, 2024 | PATEL, TUSHAR | reporter.nih.gov |
| Multifunctional Nanoparticle Platform to Prevent Alcohol-Associated HCC Development | NIH | National Cancer Institute | 2023 to 2025 | $698,619 | July 3, 2023 | August 1, 2025 | MENON, JYOTHI UNNIKRISHNA | reporter.nih.gov |
| Serotonergic antidepressants as liver tumor preventives | NIH | National Cancer Institute | 2021 to 2022 | $697,688 | December 13, 2017 | November 30, 2023 | EVASON, KIMBERLEY JANE | reporter.nih.gov |
| Developing ribosome biogenesis inhibitors for the prevention of cancer | NIH | National Cancer Institute | 2024 to 2025 | $697,000 | May 21, 2024 | April 30, 2027 | BUSZCZAK, MICHAEL | reporter.nih.gov |
| A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy | NIH | National Cancer Institute | 2025 | $695,955 | September 19, 2023 | August 31, 2028 | KARIN, MICHAEL | reporter.nih.gov |
| Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies | NIH | National Cancer Institute | 2025 | $693,781 | April 14, 2025 | March 31, 2030 | EL-BARDEESY, NABEEL | reporter.nih.gov |
| EphA1 homotypic and EphA1-EphA2 heterotypic interactions in cell regulation | NIH | National Cancer Institute | 2025 | $693,134 | December 5, 2024 | November 30, 2029 | WANG, BINGCHENG | reporter.nih.gov |
| FGFR4 intracellular domain promotes tumor progression in cholangiocarcinoma | NIH | National Cancer Institute | 2021 to 2022 | $689,636 | January 1, 2018 | December 31, 2023 | MOTT, JUSTIN L. | reporter.nih.gov |
| Understanding and Targeting Transcriptional Master Regulators in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2025 | $687,679 | December 15, 2024 | November 30, 2029 | SCHWABE, ROBERT F. | reporter.nih.gov |
| Mutant p53 as actionable cancer-specific target | NIH | National Cancer Institute | 2021 to 2022 | $681,979 | April 1, 2013 | May 31, 2025 | MOLL, UTE MARTHA | reporter.nih.gov |
| Investigating multifactorial beta-catenin activation in hepatocellular cancers | NIH | National Cancer Institute | 2021 to 2022 | $678,678 | January 7, 2021 | February 28, 2022 | CHEN, XIN | reporter.nih.gov |
| Integrated molecular epidemiologic analysis of the one-carbon metabolism pathway and risk of HCC | NIH | National Cancer Institute | 2021 to 2024 | $678,224 | April 1, 2020 | March 31, 2025 | ANTWI, SAMUEL O. | reporter.nih.gov |
| Transplantation of Discarded Livers Following Normothermic Machine Perfusion: A Multicenter RESTORE Trial | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $677,786 | March 15, 2023 | February 28, 2025 | CHAPMAN, WILLIAM C | reporter.nih.gov |
| Glycan Biomarkers for Cholangiocarcinoma | NIH | National Cancer Institute | 2025 | $671,384 | December 5, 2024 | November 30, 2029 | MEHTA, ANAND S. | reporter.nih.gov |
| TAZ and YAP in Non-Alcoholic Steatohepatitis and its Complications | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $664,138 | January 1, 2018 | December 31, 2021 | TABAS, IRA A | reporter.nih.gov |
| Catheter-Directed Image-Guided Delivery of Cytostatic and Cytotoxic Combination Therapy to Liver Tumors | NIH | National Cancer Institute | 2021 to 2022 | $663,607 | April 1, 2018 | March 31, 2024 | KIM, DONG-HYUN | reporter.nih.gov |
| Multilevel Determinants of Socioeconomic Disparities in Geographic Late Stage Hepatocellular Carcinoma Hotspots | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $663,001 | July 25, 2022 | March 31, 2027 | ZHOU, KALI | reporter.nih.gov |
| Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors | NIH | National Cancer Institute | 2024 to 2025 | $657,145 | May 14, 2024 | April 30, 2027 | CAO, SHUGENG | reporter.nih.gov |
| Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health. | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $654,480 | September 25, 2022 | June 30, 2027 | TRAN, NGUYEN H | reporter.nih.gov |
| Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 | $652,359 | September 14, 2018 | August 31, 2023 | MISHRA, LOPA | reporter.nih.gov |
| Protein and redox homeostasis in cancer development and therapy | NIH | National Cancer Institute | 2021 to 2022 | $651,343 | April 14, 2008 | June 30, 2024 | ZONG, WEI-XING | reporter.nih.gov |
| Large aperture and wideband modular ultrasound arrays for the diagnosis of liver cancer | NIH | National Cancer Institute | 2021 | $649,599 | March 8, 2017 | February 28, 2023 | FERRARA, KATHERINE W | reporter.nih.gov |
| Steatotic Liver Promotes Metastatic Niche: Role of Hepatic Stellate Cells | NIH | National Cancer Institute | 2025 | $646,739 | April 1, 2025 | March 31, 2030 | SEKI, EKIHIRO | reporter.nih.gov |
| Tumor-associated pDC (TApDC) in liver cancer with HIV infection | NIH | National Cancer Institute | 2025 | $634,061 | December 5, 2024 | November 30, 2029 | SU, LISHAN | reporter.nih.gov |
| Light-Activated SIte-Specific Conjugation (LASIC) to accelerate clinical translation of catheter-directed antibody-drug-conjugate labeled theranostic microbubbles in an Oncopig liver tumor model | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $630,000 | September 1, 2025 | August 31, 2028 | CHIANG, CHIH-SHENG J | reporter.nih.gov |
| Improving Access to Curative Therapies for Hepatocellular Carcinoma | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $610,032 | September 25, 2022 | June 30, 2026 | NEPHEW, LAUREN | reporter.nih.gov |
| Protein Phosphatase Control of AMPK Function | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $603,346 | April 1, 2019 | December 31, 2024 | KONG, MEI | reporter.nih.gov |
| A Novel Nanodrug for Metabolic Disease Treatment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $594,547 | September 2, 2024 | August 31, 2025 | WAN, YU-JUI YVONNE | reporter.nih.gov |
| Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH | NIH | National Cancer Institute | 2025 | $593,042 | December 10, 2024 | November 30, 2029 | DHANASEKARAN, RENUMATHY | reporter.nih.gov |
| Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics | NIH | National Cancer Institute | 2025 | $580,238 | January 10, 2025 | December 31, 2029 | DEBES, JOSE DANIEL | reporter.nih.gov |
| Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug Delivery | NIH | National Cancer Institute | 2021 | $576,664 | April 1, 2017 | March 31, 2024 | PAULMURUGAN, RAMASAMY | reporter.nih.gov |
| The Impact of Frailty on Liver Transplant Outcomes in Older Adults with Hepatocellular Carcinoma | NIH | National Institute on Aging | 2023 to 2025 | $566,229 | January 15, 2023 | December 31, 2027 | LAI, JENNIFER C. | reporter.nih.gov |
| Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $560,037 | August 15, 2023 | March 31, 2024 | DHAR, DEBANJAN | reporter.nih.gov |
| Combination of ceramide and immunotherapy in treatment of hepatocellular cancer | NIH | National Cancer Institute | 2021 | $553,074 | July 1, 2017 | June 30, 2024 | STAVELEY-O'CARROLL, KEVIN FINNBAR | reporter.nih.gov |
| Identifying phosphoribosylformylglycinamidine synthase inhibitors as a new class of purine antimetabolites | NIH | National Cancer Institute | 2025 | $549,474 | March 1, 2025 | February 29, 2028 | FRENCH, JARROD B | reporter.nih.gov |
| Promotion of fatty liver disease by the ASK1 pathway | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $548,418 | September 20, 2019 | July 31, 2022 | DAVIS, ROGER J. | reporter.nih.gov |
| Simulation Modeling of Hepatitis B Virus Elimination Strategies in Cote d'Ivoire | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $543,089 | August 1, 2022 | July 31, 2027 | MOHAREB, AMIR | reporter.nih.gov |
| Delivery optimization of a transarterial ablative therapy | NIH | National Cancer Institute | 2025 | $536,836 | March 15, 2025 | February 28, 2030 | FUENTES, DAVID | reporter.nih.gov |
| CD4 helper programs that regulate intratumoral immunity | NIH | National Cancer Institute | 2025 | $532,970 | April 1, 2025 | March 31, 2030 | KAMPHORST, ALICE OLIFFSON | reporter.nih.gov |
| Intravenous delivery of 2-hydroxypropyl-Beta-cyclodextrin for treatment of Niemann-Pick C disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $519,342 | July 10, 2017 | June 30, 2025 | DICKSON, PATRICIA I | reporter.nih.gov |
| Deciphering the Molecular Mechanisms Underlying Cholangiocarcinoma Development | NIH | National Cancer Institute | 2025 | $518,219 | April 4, 2025 | March 31, 2030 | KO, SUNGJIN | reporter.nih.gov |
| Investigating IQGAP1, a scaffold protein, in liver biology and Hepatocellular Carcinoma to overcome barriers in in vivo models | NIH | National Cancer Institute | 2023 to 2025 | $506,159 | February 20, 2023 | August 31, 2025 | DELGADO, EVAN R | reporter.nih.gov |
| Air pollution and health disparities in liver disease and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $500,531 | July 15, 2020 | May 31, 2026 | VOPHAM, TRANG | reporter.nih.gov |
| Impact of Hepatitis C and HIV coinfection on biological aging and hepatocellular carcinoma risk | NIH | Fogarty International Center | 2022 to 2023 | $500,450 | July 1, 2022 | June 30, 2025 | DEBES, JOSE DANIEL | reporter.nih.gov |
| Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $500,000 | August 1, 2023 | March 31, 2024 | DHAR, DEBANJAN | reporter.nih.gov |
| Early-stage detection of hepatocellular carcinoma with hydralazine-augmented contrast ultrasound imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $499,909 | August 11, 2025 | July 31, 2029 | SEHGAL, CHANDRA M | reporter.nih.gov |
| Role of Aflatoxin-induced DNA Damage Formation and Repair in Hepatic Mutagenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $497,335 | September 3, 2020 | August 31, 2025 | LI, WENTAO | reporter.nih.gov |
| Developing Chemical Probes to Decipher Gankyrin Biology | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $492,000 | March 1, 2021 | February 28, 2025 | MUTH, AARON | reporter.nih.gov |
| 3D Circadian Enhancer-Promoter Interactions Mediated by ESRRG in NAFLD-to-HCC Progression | NIH | National Cancer Institute | 2025 | $483,077 | June 1, 2025 | May 31, 2030 | GUAN, DONGYIN | reporter.nih.gov |
| TET1 and sex differences in alcohol associated liver tumorigenesis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $477,626 | May 2, 2025 | September 1, 2025 | HUANG, CHIUNG-KUEI | reporter.nih.gov |
| Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease | NIH | National Cancer Institute | 2021 | $473,414 | May 9, 2018 | April 30, 2023 | LUBMAN, DAVID M. | reporter.nih.gov |
| pA-regulator controlled, JMJD6 reprogrammed GPC3-CAR T cells for patients with hepatocellular carcinoma | NIH | National Cancer Institute | 2025 | $470,759 | September 1, 2025 | August 31, 2027 | HECZEY, ANDRAS A. | reporter.nih.gov |
| Investigating the Immunosuppressive Function of lncRNA CRNDE in Hepatic Tumorigenesis | NIH | National Cancer Institute | 2025 | $468,139 | March 15, 2025 | February 28, 2030 | ZHANG, JINQIANG | reporter.nih.gov |
| Development of cell-based models for fibrolamellar carcinoma | NIH | National Cancer Institute | 2022 to 2023 | $465,302 | July 1, 2022 | December 31, 2024 | VAKILI, KHASHAYAR | reporter.nih.gov |
| Modulation of RNA Binding Proteins in Xenobiotic-induced Hepatotoxicity | NIH | National Institute of Environmental Health Sciences | 2023 | $464,386 | March 9, 2023 | September 1, 2023 | SAINI, YOGESH | reporter.nih.gov |
| Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver | NIH | National Cancer Institute | 2023 | $461,844 | September 19, 2023 | August 31, 2026 | BILLINGSLEY, KELVIN L | reporter.nih.gov |
| Modulation of RNA Binding Proteins in Xenobiotic-induced Hepatotoxicity | NIH | National Institute of Environmental Health Sciences | 2024 | $459,895 | January 22, 2024 | December 31, 2028 | SAINI, YOGESH | reporter.nih.gov |
| Precise image guidance for liver cancer stereotactic body radiotherapy using element-resolved motion-compensated cone beam CT | NIH | National Cancer Institute | 2021 to 2022 | $459,552 | March 15, 2018 | June 10, 2022 | JIA, XUN | reporter.nih.gov |
| Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer | NIH | National Cancer Institute | 2021 to 2022 | $457,587 | December 27, 2017 | July 31, 2023 | DURDEN, DONALD | reporter.nih.gov |
| Ribonucleotide Reductase in Hepatoblastoma Progression and Drug Resistance | NIH | National Cancer Institute | 2021 to 2022 | $456,505 | January 1, 2021 | December 31, 2023 | ZHU, LIQIN | reporter.nih.gov |
| Hepatitis B virus integrations in KMT2B drive hepatocellular carcinoma | NIH | National Cancer Institute | 2022 | $453,403 | July 15, 2022 | June 30, 2023 | CAO, JIAN | reporter.nih.gov |
| Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer | NIH | National Cancer Institute | 2021 | $453,359 | June 1, 2017 | June 30, 2023 | CHILKOTI, ASHUTOSH | reporter.nih.gov |
| Image Guided Delivery and Evaluation of Low-Density Lipoprotein- Docosahexaenoic acid Nanoparticles for the Management of Hepatocellular Carcinoma -Diversity Supplement | NIH | National Cancer Institute | 2021 | $451,707 | June 7, 2017 | October 31, 2022 | CORBIN, IAN RONALD | reporter.nih.gov |
| Explore hepatitis B virus preS2 mutants as immune escape mutants | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $451,000 | November 10, 2022 | October 31, 2025 | LI, JISU | reporter.nih.gov |
| Hyperpolarized 13C probes for the one carbon metabolism | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $451,000 | August 1, 2023 | July 31, 2025 | KOVACS, ZOLTAN | reporter.nih.gov |
| Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $446,770 | May 1, 2021 | January 31, 2025 | CORMODE, DAVID PETER | reporter.nih.gov |
| Single-Shot Quantitative X-ray Imaging for Interventional Procedures | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $445,305 | July 1, 2020 | March 31, 2024 | WANG, ADAM S | reporter.nih.gov |
| Gut microbiota-derived signaling in liver carcinogenesis and cancer treatment | NIH | National Cancer Institute | 2021 to 2023 | $440,819 | September 19, 2019 | August 31, 2024 | HU, YING | reporter.nih.gov |
| Novel circulating biomarker digital scores for assessing treatment response in liver cancer | NIH | National Cancer Institute | 2023 | $436,472 | September 1, 2023 | August 31, 2025 | YANG, JU DONG | reporter.nih.gov |
| A Novel Janus Bead Blood Assay for Point-of-Care Assessment of HCV Viral Load and Associated Liver Damage | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $430,375 | July 8, 2024 | May 31, 2026 | CHANG, HSUEH-CHIA | reporter.nih.gov |
| Development of the GlycoHCCTyper for the early detection of HCC | NIH | National Cancer Institute | 2022 | $428,443 | March 1, 2022 | February 29, 2024 | CASTELLINO, STEPHEN | reporter.nih.gov |
| CROSSTALK BETWEEN GUT MICROBIOTA AND HEPATOCELLULAR CARCINOMA INDUCED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE | NIH | National Cancer Institute | 2024 | $426,425 | August 1, 2024 | July 31, 2026 | JALAL, PRASUN KUMAR | reporter.nih.gov |
| Role of DDX5 in Hepatitis B virus transcription and hepatocarcinogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,559 | February 16, 2023 | June 30, 2025 | KAZEMIAN, MAJID | reporter.nih.gov |
| Jumonji enzyme action in hepatocellular carcinoma onset | NIH | National Cancer Institute | 2024 to 2025 | $421,685 | February 1, 2024 | January 30, 2026 | MARTINEZ, ELISABETH D | reporter.nih.gov |
| Targeting a Novel Secreted Immune Checkpoint to Enhance Liver Cancer Immunotherapy | NIH | National Cancer Institute | 2025 | $421,685 | August 1, 2025 | July 31, 2027 | DENG, YALAN | reporter.nih.gov |
| Exploratory studies of cellular resistance to MTA-cooperative PRMT5 inhibitors in MTAP-loss tumors. | NIH | National Cancer Institute | 2025 | $420,400 | August 1, 2025 | July 31, 2027 | AHNERT, JORDI RODON | reporter.nih.gov |
| Characterization of 5'-human-HBV-3' RNA species transcribed from integrated HBV DNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $419,275 | February 1, 2024 | December 31, 2026 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Investigating the molecular and cellular mechanisms of virus-associated hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $419,131 | September 1, 2019 | March 31, 2026 | CHEN, HSUAN-AN | reporter.nih.gov |
| DNP-MRSI for the Detection of Latent, Treatment-Resistant Cellular Domains in HCC | NIH | National Cancer Institute | 2022 | $416,075 | September 9, 2022 | August 31, 2025 | GADE, TERENCE P | reporter.nih.gov |
| Mast Cell Regulation of Alcohol-Induced Liver Damage | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $416,063 | August 18, 2022 | July 31, 2024 | FRANCIS, HEATHER L | reporter.nih.gov |
| Antivascular ultrasound therapy of primary liver neoplasia | NIH | National Cancer Institute | 2021 | $415,179 | January 1, 2017 | December 31, 2022 | SEHGAL, CHANDRA M | reporter.nih.gov |
| Modulating the immuno-metabolic interplay in liver cancer with cryoablation | NIH | National Cancer Institute | 2023 to 2024 | $412,832 | April 1, 2023 | March 31, 2026 | COMAN, DANIEL | reporter.nih.gov |
| Clonal drivers of resistance to immune checkpoint blockade in liver malignancies | NIH | National Cancer Institute | 2022 to 2023 | $412,757 | January 12, 2022 | December 31, 2023 | GENOVESE, GIANNICOLA | reporter.nih.gov |
| Characterization of endovascular ablative therapies with computational modeling | NIH | National Cancer Institute | 2022 to 2023 | $412,757 | May 26, 2022 | April 30, 2025 | FUENTES, DAVID | reporter.nih.gov |
| Discovery of chemoresistant tumor subclones in pediatric liver cancers | NIH | National Cancer Institute | 2024 to 2025 | $412,651 | December 15, 2023 | November 30, 2026 | SUMAZIN, PAVEL | reporter.nih.gov |
| Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $412,434 | July 3, 2018 | June 30, 2023 | LESINSKI, GREGORY B. | reporter.nih.gov |
| Development and application of non-thermal high frequency IRE to treat hepatic tumors | NIH | National Cancer Institute | 2024 | $411,633 | April 1, 2020 | March 31, 2026 | DAVALOS, RAFAEL VIDAL | reporter.nih.gov |
| MiRNAs in hepatocellular carcinoma development and treatment | NIH | National Cancer Institute | 2021 | $410,875 | January 25, 2011 | May 31, 2023 | HUANG, WENDONG | reporter.nih.gov |
| FABP4 Released from Steatotic Hepatocytes in Alcoholic Liver Disease Enhances Hepatic Tumor Progression | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $410,813 | September 25, 2021 | August 31, 2024 | MCKILLOP, IAIN HUGH | reporter.nih.gov |
| Mechanisms that promote hepatocellular carcinoma due to chronic ethanol exposure | NIH | National Institute on Alcohol Abuse and Alcoholism | 2023 to 2024 | $408,368 | May 5, 2023 | April 30, 2026 | TUMA, PAMELA L. | reporter.nih.gov |
| Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC) | NIH | National Cancer Institute | 2021 to 2022 | $404,288 | July 9, 2018 | June 30, 2023 | DHANASEKARAN, RENUMATHY | reporter.nih.gov |
| Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $402,600 | April 1, 2021 | March 31, 2022 | KUGEL, SITA | reporter.nih.gov |
| Bacterial DNA as a Diagnostic Biomarker of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2023 | $402,565 | February 1, 2022 | January 31, 2025 | ZARRINPAR, AMIR | reporter.nih.gov |
| Dietary fructose and NASH/HCC progression | NIH | National Cancer Institute | 2024 to 2025 | $402,400 | April 1, 2024 | March 31, 2027 | SONG, MING | reporter.nih.gov |
| Targeting CXCR2+ PMN-MDSCs for immunotherapy of hepatoblastoma | NIH | National Cancer Institute | 2025 | $402,400 | May 15, 2025 | April 30, 2027 | CHEN, XIN | reporter.nih.gov |
| Salmonella as a vector for delivery of oncolytic viruses to hepatocellular carcinoma | NIH | National Cancer Institute | 2024 | $402,147 | June 1, 2024 | May 31, 2026 | FORBES, NEIL S. | reporter.nih.gov |
| Contrast-enhanced ultrasound evaluation of radioembolization treatment response | NIH | National Cancer Institute | 2025 | $401,115 | August 1, 2025 | July 31, 2027 | EISENBREY, JOHN | reporter.nih.gov |
| In vivo feasibility of a smart needle ablation treatment for liver cancer | NIH | National Cancer Institute | 2023 | $400,000 | April 1, 2023 | March 31, 2025 | MASHAL, ALIREZA | reporter.nih.gov |
| Development of a novel liver-specific positron emission tomography tracer | NIH | National Cancer Institute | 2025 | $400,000 | September 15, 2025 | August 31, 2026 | VAKILI, KHASHAYAR | reporter.nih.gov |
| Integration of non-invasive deep tissue microwave thermometry in the VectRx hyperthermia device in a transgenic liver tumor pig model | NIH | National Cancer Institute | 2023 | $399,999 | August 1, 2023 | July 31, 2024 | FLORIANO, PIERRE N | reporter.nih.gov |
| Developing engineered inhibitors of tRNA modifying enzymes | NIH | National Cancer Institute | 2025 | $399,966 | June 23, 2025 | May 31, 2026 | DRAYCOTT, AUSTIN STRATTON | reporter.nih.gov |
| Proteomic signatures to predict drug response in cancer | NIH | National Cancer Institute | 2024 to 2025 | $399,830 | April 17, 2024 | March 31, 2026 | ONG, SHAO-EN | reporter.nih.gov |
| 3D Shear-wave Imaging Transducer for Liver Cancer Screening | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 | $399,617 | September 16, 2022 | September 15, 2024 | LAY, HOLLY SUSAN | reporter.nih.gov |
| Water-based liquid embolic agent for the treatment of vascular rich tumors | NIH | National Cancer Institute | 2023 | $399,528 | July 5, 2023 | June 30, 2025 | YUKI, ICHIRO | reporter.nih.gov |
| Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2023 | $397,469 | December 3, 2021 | May 31, 2025 | EISENBREY, JOHN | reporter.nih.gov |
| Chronic alcohol consumption results in elevated Autotaxin levels that suppress anti-tumor immunity | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2023 | $396,742 | April 1, 2022 | September 30, 2024 | TORRES, RAUL MARTIN | reporter.nih.gov |
| Genomic lineage traces as biomarkers for human pancreatic and liver cancer | NIH | National Cancer Institute | 2024 to 2025 | $395,973 | February 6, 2024 | January 31, 2026 | MURTAUGH, LEWIS C | reporter.nih.gov |
| Preoperative immunotherapy in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2024 | $393,255 | July 1, 2023 | June 30, 2026 | LESINSKI, GREGORY B. | reporter.nih.gov |
| Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 | $392,485 | September 1, 2022 | August 31, 2023 | KULIOPULOS, ATHAN | reporter.nih.gov |
| ROS-induced SPIO Targeted Platform for Transarterial Liver Cancer Therapy | NIH | National Cancer Institute | 2021 to 2022 | $391,653 | March 1, 2021 | February 29, 2024 | FARSAD, KHASHAYAR | reporter.nih.gov |
| Acoustic Droplet Initiated Radiosensitivity of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2023 to 2024 | $390,176 | April 1, 2023 | March 31, 2026 | EISENBREY, JOHN | reporter.nih.gov |
| Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer | NIH | National Cancer Institute | 2023 | $390,037 | December 27, 2017 | July 31, 2025 | DURDEN, DONALD | reporter.nih.gov |
| Consortium on Translational Research in Early Detection of Liver Cancer: Data Management and Coordinating Center (DMCC) | NIH | National Cancer Institute | 2021 | $389,953 | September 17, 2018 | March 31, 2022 | FENG, ZIDING | reporter.nih.gov |
| Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer | NIH | National Cancer Institute | 2021 to 2022 | $387,838 | January 1, 2021 | December 31, 2023 | LIM, CAROL S. | reporter.nih.gov |
| Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2023 | $387,838 | May 27, 2022 | March 31, 2025 | MALANY, SIOBHAN | reporter.nih.gov |
| Mechanisms of lipid droplet trafficking in hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2024 | $385,717 | June 2, 2023 | May 31, 2025 | SCHOTT, MICAH | reporter.nih.gov |
| CRISPR and Humanized mice-based Discovery of a Novel Drug target for HCC Therapy | NIH | National Cancer Institute | 2024 to 2025 | $381,830 | April 1, 2024 | September 30, 2026 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| Cellular Sources of Pathological Stromal Variants | NIH | National Cancer Institute | 2021 to 2022 | $376,205 | July 1, 2021 | June 30, 2024 | ANGEL, PEGGI M | reporter.nih.gov |
| Mechanism-based combination therapy for cholangiocarcinoma | NIH | National Cancer Institute | 2023 to 2024 | $373,152 | April 5, 2023 | March 31, 2026 | YOON, KARINA J | reporter.nih.gov |
| NANOG-positive cancer stem cells in liver oncogenesis induced by alcohol and HCV | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $371,250 | September 1, 2017 | May 31, 2023 | MACHIDA, KEIGO | reporter.nih.gov |
| Molecular mechanism of alcohol-associated liver tumor development | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $371,250 | September 1, 2017 | June 30, 2024 | ZHONG, SHUPING | reporter.nih.gov |
| Signaling pathways during hepatocarcinogenesis | NIH | National Cancer Institute | 2021 | $369,431 | March 1, 2020 | February 28, 2022 | CHEN, XIN | reporter.nih.gov |
| Targeting Oncogenic Drivers in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $365,310 | March 7, 2022 | February 28, 2026 | BOUDREAU, MATTHEW W | reporter.nih.gov |
| A novel multi-analyte algorithmic assay diagnostic for hepatocellular carcinoma (HCC). | NIH | National Cancer Institute | 2025 | $364,763 | June 20, 2025 | November 30, 2026 | BISWAL, BOBBY KUMAR | reporter.nih.gov |
| Use of Peripheral Blood Mononuclear Cells Mitochondrial DNA Content to Detect Hepatocellular Carcinoma in Hepatitis B Virus Infected Nigerians. | NIH | Fogarty International Center | 2023 to 2025 | $357,587 | July 27, 2023 | April 30, 2028 | ADISA, RAHMAT ADETUTU | reporter.nih.gov |
| UBIQUIBODY PLATFORM FOR TARGETED DEGRADATION OF ONCOGENIC FUSION PROTEINS | NIH | National Cancer Institute | 2023 | $354,908 | February 27, 2023 | February 26, 2024 | BARNETT, MATHEW | reporter.nih.gov |
| SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA | NIH | National Cancer Institute | 2023 | $353,412 | February 28, 2023 | February 27, 2024 | SIELECKI, THAIS | reporter.nih.gov |
| Understanding the Determinants of Racial/Ethnic Disparities in Liver Cancer and Chronic Liver Disease in Understudied and High-Risk Populations | NIH | National Cancer Institute | 2021 | $350,258 | March 6, 2018 | August 31, 2023 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Precise image guidance for liver cancer stereotactic body radiotherapy using element-resolved motion-compensated cone beam CT | NIH | National Cancer Institute | 2022 | $347,188 | March 15, 2018 | February 29, 2024 | JIA, XUN | reporter.nih.gov |
| Early life aflatoxin B1 exposure and epigenetic programming in Nigerian Newborns | NIH | Fogarty International Center | 2022 to 2025 | $346,752 | September 21, 2022 | June 30, 2027 | ROTIMI, OLUWAKEMI ANUOLUWAPO | reporter.nih.gov |
| Improving the Diagnosis of Liver Disease in Primary Care Patients with Abnormal Liver Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $344,980 | July 17, 2018 | August 31, 2023 | SCHREINER, ANDREW DAVID | reporter.nih.gov |
| Mechanisms of Hepatocyte Transformation by the Hepatitis B Virus X Protein | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $344,520 | May 1, 1993 | February 28, 2023 | ANDRISANI, OURANIA M. | reporter.nih.gov |
| An immunocompetent platform for the characterization and discovery of novel therapeutics for hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2023 | $343,200 | September 1, 2022 | August 31, 2024 | RIALDI, ALEXANDER | reporter.nih.gov |
| Interplay between Dietary Fiber and Gut Microbiota in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 | $342,592 | July 1, 2017 | June 30, 2023 | VIJAY-KUMAR, MATAM | reporter.nih.gov |
| An Inducible Swine Hepatocellular Carcinoma Platform for Enhanced Therapeutic Development | NIH | National Cancer Institute | 2023 | $342,154 | September 1, 2023 | January 8, 2025 | KORPELA, DEREK MATTHEW | reporter.nih.gov |
| DR. EPS: Drug Repurposing for Extended Patient Survival | NIH | National Library of Medicine | 2021 to 2022 | $341,836 | September 21, 2019 | August 31, 2024 | GARMIRE, LANA X | reporter.nih.gov |
| Hepatitis C virus infection and mechanism of liver disease progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $340,875 | April 1, 2017 | March 31, 2024 | RAY, RANJIT | reporter.nih.gov |
| Image-Guided Transcatheter Delivery of Natural Killer Cell Therapy Augmented with IFN-Gamma Eluting Microspheres | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $340,099 | September 1, 2018 | May 31, 2023 | KIM, DONG-HYUN | reporter.nih.gov |
| MKK4 Regulation of Liver Regeneration after Resection of Colorectal Metastasis or Hilar Cholangiocarcinoma | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $322,800 | August 13, 2025 | June 30, 2028 | NYBERG, SCOTT LYLE | reporter.nih.gov |
| Translational Development of a Small Molecule for the Treatment of HBV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $320,863 | September 22, 2025 | August 31, 2027 | KAY, HEIDI A | reporter.nih.gov |
| Computational design and evaluation of peptide-guided protein degraders | NIH | National Institute of General Medical Sciences | 2024 | $313,372 | March 1, 2024 | February 28, 2025 | CAMARGO, LUIZ MIGUEL QUINN | reporter.nih.gov |
| Inhibitors of ENPP1 for the treatment of hepatocellular carcinoma | NIH | National Cancer Institute | 2025 | $306,739 | September 12, 2025 | August 31, 2026 | SENGUPTA, DEEPA | reporter.nih.gov |
| National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantation | NIH | National Cancer Institute | 2023 to 2024 | $306,076 | July 1, 2023 | June 30, 2024 | ARNOLD, KATELYN | reporter.nih.gov |
| Diabetes and extracellular matrix in NASH | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $304,335 | March 20, 2010 | January 31, 2023 | TOROK, NATALIE J. | reporter.nih.gov |
| Personalized cancer drug repurposing using single cell RNA-Seq data | NIH | Office of the Director, National Institutes of Health | 2025 | $303,258 | June 10, 2025 | May 31, 2026 | GARMIRE, LANA X | reporter.nih.gov |
| Epidemiology of the gut-liver axis and hepatocellular carcinoma risk in a multiethnic liver cirrhosis cohort: defining the role of bacteria, metabolites, and glycoproteins | NIH | National Cancer Institute | 2024 | $300,000 | September 11, 2024 | August 31, 2025 | HUSSAIN, SHEHNAZ KHURSHEED | reporter.nih.gov |
| Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,000 | September 11, 2025 | August 31, 2027 | FULLER, DEBORAH H. | reporter.nih.gov |
| Exosome-mediated therapy for liver cancer | NIH | National Cancer Institute | 2024 to 2025 | $294,970 | January 12, 2024 | December 31, 2026 | KRAITCHMAN, DARA L | reporter.nih.gov |
| Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER) | NIH | National Institute on Aging | 2021 | $293,756 | August 15, 2020 | July 31, 2022 | CHAK, ERIC W | reporter.nih.gov |
| Deciphering the role of mitochondrial metabolism in liver cancer | NIH | National Cancer Institute | 2024 to 2025 | $284,132 | March 1, 2024 | December 31, 2026 | UNLU, GOKHAN | reporter.nih.gov |
| Liver disease impact on myeloid cells driving immunotherapy resistance in hepatocellular carcinoma | NIH | National Cancer Institute | 2025 | $282,053 | March 1, 2025 | February 28, 2030 | KEENAN, BRIDGET | reporter.nih.gov |
| Defining pro-metastatic and endothelial-regulatory roles for LIN28B in hepatocellular carcinoma | NIH | National Cancer Institute | 2022 | $271,934 | August 1, 2022 | July 31, 2023 | FRANSES, JOSEPH WANG | reporter.nih.gov |
| Defining mechanisms of immunotherapy resistance and targeting TIGIT in hepatobiliary cancers | NIH | National Cancer Institute | 2025 | $270,981 | August 20, 2025 | July 31, 2030 | HSIEH, DAVID | reporter.nih.gov |
| Metabolic rewiring regulates cancer growth and tumor-associated immune responses | NIH | National Cancer Institute | 2021 to 2023 | $266,502 | February 1, 2020 | May 25, 2023 | ZHAO, STEVEN | reporter.nih.gov |
| Feasibility of a Multi-Phase Algorithmic Non-Thermal Ablation Technology for the Treatment of Inoperable Tumors | NIH | National Cancer Institute | 2022 | $259,549 | September 16, 2022 | August 31, 2025 | FONG, JORDAN | reporter.nih.gov |
| cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2022 | $256,610 | September 1, 2021 | August 31, 2024 | NAGALO, BOLNI MARIUS | reporter.nih.gov |
| A Biliary Tract-Specific Fluorescence Image-guided Surgery | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $256,579 | September 23, 2021 | September 22, 2023 | CHA, RICHARD JAEPYEONG | reporter.nih.gov |
| Optimizing Thermal Ablation for Colon Cancer Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures | NIH | National Cancer Institute | 2022 | $251,889 | September 12, 2019 | February 29, 2024 | SOFOCLEOUS, CONSTANTINOS THASOS | reporter.nih.gov |
| Clinical Translation of Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin | NIH | National Cancer Institute | 2024 | $249,873 | April 1, 2024 | March 31, 2026 | KUTSCHER, HILLIARD | reporter.nih.gov |
| MDCT Quantification of hepatic tumor viability for assessment of cancer therapy | NIH | National Cancer Institute | 2021 | $240,583 | September 16, 2014 | April 30, 2023 | WU, YIN | reporter.nih.gov |
| Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer | NIH | National Cancer Institute | 2023 | $237,330 | May 1, 2023 | April 18, 2024 | LI, GUANGFU | reporter.nih.gov |
| Imaging Liver Cancer Proliferation | NIH | National Cancer Institute | 2021 | $236,635 | August 15, 2016 | July 31, 2024 | LEE, ZHENGHONG | reporter.nih.gov |
| Implementation of automated staining in conjunction with spatial analyses | NIH | Office of the Director, National Institutes of Health | 2023 | $235,697 | July 1, 2023 | June 30, 2024 | THOMPSON, E. AUBREY | reporter.nih.gov |
| Vinyl chloride-induced changes to the epitranscriptome: interaction with diet | NIH | National Institute of Environmental Health Sciences | 2021 | $234,646 | April 6, 2020 | March 31, 2023 | BEIER, JULIANE I | reporter.nih.gov |
| Elucidation of the alcohol effect on tumor suppressor genes | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $227,844 | September 1, 2025 | August 31, 2027 | DONG, X. CHARLIE | reporter.nih.gov |
| Optical and electromagnetic tracking guidance for hepatic interventions | NIH | National Cancer Institute | 2021 | $225,397 | March 2, 2017 | June 30, 2023 | MAHMOOD, UMAR | reporter.nih.gov |
| Biomimetic NanoVilli Chips for Extracellular Vesicles in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 | $221,408 | April 1, 2020 | March 31, 2023 | ZHU, YAZHEN | reporter.nih.gov |
| CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment | NIH | National Cancer Institute | 2022 | $215,585 | January 15, 2022 | December 31, 2022 | LIU, DONGFANG | reporter.nih.gov |
| Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer | NIH | National Cancer Institute | 2021 | $214,949 | April 1, 2019 | August 31, 2021 | CHAUDHURI, AADEL | reporter.nih.gov |
| Regulation of Genome Stability and Structure by the Nucleosome Remodeler HELLS in Leukemia | NIH | National Cancer Institute | 2023 to 2024 | $213,638 | September 1, 2023 | May 30, 2025 | PRESCOTT, NICHOLAS | reporter.nih.gov |
| Aflatoxin exposure and hepatocellular carcinoma in Mexico | NIH | Fogarty International Center | 2021 to 2022 | $210,818 | August 1, 2020 | April 30, 2023 | LAJOUS, MARTIN | reporter.nih.gov |
| The role and regulation of p53 in obesity-induced liver cancer | NIH | National Cancer Institute | 2021 to 2023 | $209,964 | January 1, 2021 | December 31, 2023 | ZHU, CHANGYU | reporter.nih.gov |
| Investigating METTL5-regulated translational changes in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $209,456 | July 1, 2020 | June 30, 2025 | SEPICH, CARALINE LEE | reporter.nih.gov |
| Proteomics Study of Non-viral Related Hepatocellular Carcinoma Risk | NIH | National Cancer Institute | 2021 | $208,492 | December 12, 2019 | November 30, 2023 | ZHANG, XUEHONG | reporter.nih.gov |
| Click Chemistry-Mediated Microfluidic Sorting for HCC CTCs | NIH | National Cancer Institute | 2021 | $203,580 | April 2, 2019 | March 31, 2023 | ZHU, YAZHEN | reporter.nih.gov |
| Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $200,000 | January 19, 2019 | November 30, 2022 | SHETH, RAHUL ANIL | reporter.nih.gov |
| Reducing the Burden of Hepatocellular Carcinoma Among Migrant Populations: Improving prevention and outcomes through disease modeling | NIH | National Cancer Institute | 2021 to 2024 | $199,856 | February 1, 2021 | January 31, 2025 | VALLES, KENNETH ANDREW | reporter.nih.gov |
| Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer | NIH | National Cancer Institute | 2025 | $196,029 | April 1, 2025 | March 31, 2028 | WU, MENG-JU | reporter.nih.gov |
| Stearoyl-CoA Desaturase in Alcohol-Promoted Liver Tumorigenesis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $195,588 | May 1, 2017 | April 30, 2023 | LAI, KEANE | reporter.nih.gov |
| Molecular and cancer-related roles of ACLY exon 14 | NIH | National Cancer Institute | 2021 to 2024 | $182,478 | June 1, 2021 | May 19, 2025 | SUPPLEE, JULIANNA | reporter.nih.gov |
| Exploiting metabolic reprogramming to target IDH1 mutated cholangiocarcinoma | NIH | National Cancer Institute | 2021 | $178,200 | March 1, 2020 | February 28, 2022 | SHI, LEI | reporter.nih.gov |
| Hereditary Genetics of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 | $177,876 | February 1, 2022 | June 30, 2022 | WANGENSTEEN, KIRK J | reporter.nih.gov |
| Innate Immune Signaling in Fibrolamellar Carcinoma | NIH | National Cancer Institute | 2023 | $177,000 | September 15, 2023 | August 31, 2025 | HANSEN, STEEN HENNING | reporter.nih.gov |
| CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment | NIH | National Cancer Institute | 2023 | $175,309 | January 15, 2022 | December 31, 2024 | LIU, DONGFANG | reporter.nih.gov |
| Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $174,867 | June 1, 2022 | May 31, 2027 | VOSS, DILLON MATTHEW | reporter.nih.gov |
| A new mouse model for testing splice-switching therapies in IGF-driven cancers | NIH | National Cancer Institute | 2021 to 2022 | $168,010 | March 16, 2021 | February 28, 2025 | CHANDLER, DAWN S | reporter.nih.gov |
| Comprehensive Intellectual Property, Reimbursement, and Licensing Strategy for ImCare Biotech's Diagnostic Product Seravue | NIH | National Cancer Institute | 2021 | $166,729 | September 1, 2012 | July 31, 2021 | LU, XUANYONG | reporter.nih.gov |
| Burden Among Informal Caregivers of Older Adults Receiving Treatments for Hepatocellular Carcinoma | NIH | National Institute on Aging | 2021 | $166,702 | September 15, 2020 | May 31, 2023 | WOODRELL, CHRISTOPHER | reporter.nih.gov |
| Inflammation and Hepatocellular Carcinoma: A Multiomics Approach to Improve Early Detection, Causal Inference, and Lifestyle Based Prevention | NIH | National Cancer Institute | 2025 | $165,883 | February 1, 2025 | January 31, 2027 | ZHANG, XINYUAN | reporter.nih.gov |
| Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles | NIH | National Cancer Institute | 2025 | $161,400 | August 1, 2025 | July 31, 2027 | POVERO, DAVIDE | reporter.nih.gov |
| Investigating Immunosuppression in Beta-catenin-mutated Hepatocellular Carcinoma for Improved Precision Medicine Therapeutics | NIH | National Cancer Institute | 2023 to 2025 | $161,206 | July 1, 2023 | June 30, 2026 | LEHRICH, BRANDON | reporter.nih.gov |
| Role of Nod2 and AMP-kinase in obesity-associated liver cancer | NIH | National Cancer Institute | 2022 to 2023 | $158,500 | September 1, 2022 | August 31, 2024 | GUPTA, DIPIKA | reporter.nih.gov |
| Evaluation of voltage-gated calcium ion channels as a therapeutic target in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2022 to 2023 | $155,916 | July 1, 2022 | June 11, 2024 | LIU, ANNIE | reporter.nih.gov |
| Define the oncogenic role of Plk1 during hepatocellular carcinoma development using a genetically modified mouse model | NIH | National Cancer Institute | 2023 | $155,250 | September 1, 2023 | August 31, 2025 | FU, ZHENG | reporter.nih.gov |
| The mechanism of gp78 ubiquitin ligase in suppressing hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2022 | $154,000 | December 1, 2020 | May 31, 2024 | XIE, YOUMING | reporter.nih.gov |
| Elucidating molecular mechanisms of cabozantinib resistance in liver cancer | NIH | National Cancer Institute | 2024 to 2025 | $154,000 | March 5, 2024 | February 28, 2027 | QIU, WEI | reporter.nih.gov |
| Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | NIH | National Cancer Institute | 2025 | $145,336 | March 1, 2025 | February 28, 2027 | JI, LIANGLIANG | reporter.nih.gov |
| Role of necroptosis in inflammation and NAFLD to HCC progression | NIH | National Cancer Institute | 2022 to 2023 | $145,000 | March 1, 2022 | February 29, 2024 | SATHYASEELAN, DEEPA | reporter.nih.gov |
| Machine Learning Inspired Physical Models in Organs | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $140,482 | September 1, 2021 | August 31, 2024 | TZOLOVA, BILYANA | reporter.nih.gov |
| The Role of Glucose-6-Phosphatase in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $139,229 | February 3, 2021 | May 4, 2024 | KELEKAR, SHERWIN | reporter.nih.gov |
| A New Strategy to Increase Proteotoxic Cell Death in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2022 | $127,200 | February 1, 2021 | January 31, 2024 | PEREZ-STABLE, CARLOS M | reporter.nih.gov |
| Syndecan-1 structure-function analysis in relation to iron metabolism | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $123,412 | May 1, 2023 | April 30, 2026 | LEAL, STEPHANIE | reporter.nih.gov |
| Nuclear envelope and predisposition to hepatic neoplasia | NIH | National Cancer Institute | 2023 | $116,766 | August 1, 2023 | February 29, 2024 | SHIN, JI-YEON | reporter.nih.gov |
| Mechanisms of tumor initiation upon disruption of the Rb/E2f interaction | NIH | National Cancer Institute | 2021 | $106,412 | April 1, 2021 | September 6, 2021 | VIATOUR, PATRICK | reporter.nih.gov |
| T Cell Responses to Neoantigens in Fibrolamellar Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $104,989 | April 1, 2021 | June 19, 2023 | KIRK, ALLISON MACKENZIE | reporter.nih.gov |
| Noninvasive assessment of IDH mutation status in intrahepatic cholangiocarcinoma | NIH | National Cancer Institute | 2024 to 2025 | $98,512 | May 1, 2024 | April 30, 2027 | ZAVRIYEV, ALEXANDER | reporter.nih.gov |
| Defining Protein Signature of Vascular Invasion in Hepatoblastoma | NIH | National Cancer Institute | 2023 to 2024 | $97,366 | April 24, 2023 | June 23, 2024 | ESPINOZA, ANDY | reporter.nih.gov |
| Investigating the Mechanism of Activation of EphA4 | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $96,668 | May 1, 2023 | April 30, 2025 | WHITEHEAD, BRIANA | reporter.nih.gov |
| Air pollution and health disparities in liver disease and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $95,025 | July 15, 2020 | March 31, 2022 | VOPHAM, TRANG | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Ut Southwestern Medical Center | Dallas, TX | 27 | $33 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 17 | $27 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 16 | $23.7 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 2 | $23 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 17 | $20.3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 10 | $20.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 13 | $19.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 13 | $19.7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 6 | $18.9 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 14 | $18.3 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 5 | $17.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 11 | $13.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 10 | $11.9 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 2 | $11.7 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 9 | $11.7 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 12 | $11.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 10 | $11.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 10 | $9.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 5 | $9.6 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 7 | $9.4 million | 0 | $0 |
| Yale University | New Haven, CT | 7 | $8.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 8 | $8.2 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 5 | $7.7 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 5 | $6.8 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 4 | $6.4 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 5 | $6.1 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 6 | $6 million | 0 | $0 |
| Salk Institute for Biological Studies | La Jolla, CA | 2 | $6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 6 | $5.8 million | 0 | $0 |
| University of California at Davis | Davis, CA | 8 | $5.4 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 6 | $5.4 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 5 | $5.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 5 | $5.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 6 | $5.2 million | 0 | $0 |
| Washington University | Saint Louis, MO | 5 | $5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 6 | $5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 3 | $5 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $4.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 4 | $4.8 million | 0 | $0 |
| Imcare Biotech, Inc. | Doylestown, PA | 3 | $4.5 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 5 | $4.5 million | 0 | $0 |
| University of Chicago | Chicago, IL | 4 | $4.1 million | 0 | $0 |
| Rockefeller University | New York, NY | 5 | $4.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 3 | $4 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 5 | $4 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 4 | $3.9 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $3.7 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 3 | $3.7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 5 | $3.6 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 4 | $3.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 2 | $3.5 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 2 | $3.5 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 3 | $3.4 million | 0 | $0 |
| Augusta University | Augusta, GA | 2 | $3.3 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 1 | $3.2 million | 0 | $0 |
| Mayo Clinic Arizona | Scottsdale, AZ | 1 | $3.2 million | 0 | $0 |
| Georgetown University | Washington, DC | 3 | $3.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 4 | $3.1 million | 0 | $0 |
| Northwestern University | Chicago, IL | 2 | $3.1 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $3 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 3 | $3 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 1 | $3 million | 0 | $0 |
| Palo Alto Veterans Instit for Research | Palo Alto, CA | 1 | $2.6 million | 0 | $0 |
| Filtro Medical Inc. | San Jose, CA | 1 | $2.6 million | 0 | $0 |
| Columbia University | New York, NY | 1 | $2.5 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 3 | $2.4 million | 0 | $0 |
| Immunophotonics, Inc. | St. Louis, MO | 1 | $2.4 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 4 | $2.4 million | 0 | $0 |
| XL Sci-Tech, Inc. | Richland, WA | 1 | $2.3 million | 0 | $0 |
| Pop Biotechnologies, INC | Buffalo, NY | 2 | $2.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 3 | $2.2 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 3 | $2.2 million | 0 | $0 |
| Washington State University | Pullman, WA | 1 | $2.1 million | 0 | $0 |
| George Washington University | Washington, DC | 3 | $2.1 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 3 | $2.1 million | 0 | $0 |
| Sus Clinicals, Inc. | Cincinnati, OH | 1 | $2 million | 0 | $0 |
| 7 Hills Pharma, LLC | Houston, TX | 1 | $2 million | 0 | $0 |
| Earlydiagnostics, Inc. | Los Angeles, CA | 1 | $2 million | 0 | $0 |
| Eximius Diagnostics Corp | Los Angeles, CA | 1 | $2 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 2 | $1.9 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 1 | $1.9 million | 0 | $0 |
| Lankenau Institute for Medical Research | Wynnewood, PA | 1 | $1.8 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 1 | $1.8 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 4 | $1.8 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 2 | $1.7 million | 0 | $0 |
| California Institute of Technology | Pasadena, CA | 1 | $1.7 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 3 | $1.6 million | 0 | $0 |
| University of Rhode Island | Kingston, RI | 2 | $1.5 million | 0 | $0 |
| Feinstein Institute for Medical Research | Manhasset, NY | 1 | $1.5 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 3 | $1.4 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 4 | $1.4 million | 0 | $0 |
| Gradient Medical, Inc. | Cary, NC | 2 | $1.4 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $1.4 million | 0 | $0 |
| Glax, LLC | Wilmington, DE | 1 | $1.4 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 1 | $1.4 million | 0 | $0 |
| Queen's Medical Center | Honolulu, HI | 1 | $1.3 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 2 | $1.3 million | 0 | $0 |
| Ne Scientific, Inc. | Burlington, MA | 1 | $1.2 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 1 | $1.1 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 1 | $1.1 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 257 | $143,217,944 | 0 | $0 |
| 2024 | 270 | $127,757,400 | 0 | $0 |
| 2023 | 285 | $133,342,173 | 0 | $0 |
| 2022 | 280 | $129,354,302 | 0 | $0 |
| 2021 | 249 | $110,329,860 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.396 | November 2, 2026 | Not listed | Same assistance listing 93.396 as 98 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.396 | November 20, 2026 | Not listed | Same assistance listing 93.396 as 98 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.396 | January 7, 2027 | $375,000 | Same assistance listing 93.396 as 98 awards here |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | PAR-25-221 | NIH | 93.396 | January 7, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.396 | January 25, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.396 | February 9, 2027 | $700,000 | Same assistance listing 93.396 as 98 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | PAR-25-272 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | PAR-25-279 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.396 | June 11, 2027 | $600,000 | Same assistance listing 93.396 as 98 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.396 | July 17, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.396 | October 4, 2027 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.396 | October 19, 2027 | $300,000 | Same assistance listing 93.396 as 98 awards here |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-25-301 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 98 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 98 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) | PA-25-306 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 98 awards here |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 98 awards here |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-25-043 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 98 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.